Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:1909
Name melanoma
Definition A cell type cancer that has_material_basis_in abnormally proliferating cells derives_from melanocytes which are found in skin, the bowel and the eye.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer cell type cancer melanoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
BRAF V600E Dabrafenib melanoma sensitive detail...
BRAF V600E Vemurafenib melanoma sensitive detail...
NRAS mutant Binimetinib melanoma conflicting detail...
BRAF wild-type Dabrafenib melanoma no benefit detail...
BRAF V600E/K Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 Q56P Selumetinib melanoma resistant detail...
BRAF V600E RXDX-105 melanoma sensitive detail...
BRAF wild-type RAF265 melanoma predicted - sensitive detail...
BRAF V600E PLX4720 melanoma sensitive detail...
BRAF wild-type PLX4720 melanoma resistant detail...
BRAF V600E MAP2K1 Q56P PLX4720 melanoma resistant detail...
BRAF V600E MAP2K1 P124L PLX4720 + Selumetinib melanoma sensitive detail...
BRAF V600E Sorafenib melanoma no benefit detail...
BRAF act mut Sorafenib melanoma no benefit detail...
BRAF act mut Cobimetinib melanoma sensitive detail...
MAP2K1 K57E Dabrafenib melanoma resistant detail...
BRAF V600E Encorafenib melanoma sensitive detail...
NRAS mutant Adavosertib melanoma sensitive detail...
BRAF L597S TAK-733 melanoma predicted - sensitive detail...
BRAF mutant Selumetinib melanoma sensitive detail...
BRAF wild-type Selumetinib melanoma no benefit detail...
KIT N505I Sorafenib melanoma sensitive detail...
KIT N505I Imatinib melanoma predicted - sensitive detail...
BRAF V600X Binimetinib melanoma sensitive detail...
BRAF mutant Tovorafenib melanoma sensitive detail...
BRAF V600E Refametinib melanoma sensitive detail...
BRAF V600E Selumetinib melanoma sensitive detail...
BRAF V600X Cobimetinib + Vemurafenib melanoma sensitive detail...
BRAF V600E PTEN loss Everolimus melanoma predicted - resistant detail...
BRAF wild-type Trametinib melanoma sensitive detail...
BRAF V600E Ganetespib + TAK-733 melanoma sensitive detail...
BRAF L505H Vemurafenib melanoma resistant detail...
BRAF V600E/K Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600X Dabrafenib + Trametinib melanoma sensitive detail...
BRAF mut TP53 wild-type CGM097 + Encorafenib melanoma sensitive detail...
KIT A829P Imatinib melanoma resistant detail...
KIT A829P Sunitinib melanoma resistant detail...
KIT A829P Nilotinib melanoma sensitive detail...
KIT A829P Dasatinib melanoma sensitive detail...
KIT T670I Imatinib melanoma resistant detail...
KIT T670I Nilotinib melanoma resistant detail...
KIT T670I Dasatinib melanoma resistant detail...
KIT T670I Sunitinib melanoma sensitive detail...
BRAF V600E MAP2K1 P124L Selumetinib melanoma resistant detail...
NRAS mutant Binimetinib + Ribociclib melanoma sensitive detail...
CDKN2A loss NRAS mut Abemaciclib melanoma predicted - sensitive detail...
CDKN2A loss Alvocidib melanoma sensitive detail...
BRAF V600E NRAS Q61K XL888 melanoma sensitive detail...
BRAF V600E NRAS Q61K Vemurafenib melanoma resistant detail...
BRAF mutant PLX8394 melanoma sensitive detail...
BRAF V600E Navitoclax + PLX4720 melanoma sensitive detail...
CDKN2A loss NRAS Q61K Palbociclib + Trametinib melanoma sensitive detail...
KIT mutant Nilotinib melanoma sensitive detail...
BRAF V600E CCT196969 melanoma sensitive detail...
BRAF V600E CCT241161 melanoma sensitive detail...
BRAF V600D CCT196969 melanoma sensitive detail...
BRAF V600D CCT241161 melanoma sensitive detail...
NRAS Q61L CCT241161 melanoma sensitive detail...
NRAS Q61L CCT196969 melanoma sensitive detail...
NRAS Q61L PLX4720 melanoma resistant detail...
NRAS mutant CCT196969 melanoma sensitive detail...
NRAS mutant CCT241161 melanoma sensitive detail...
BRAF V600E Gefitinib + PLX4720 melanoma sensitive detail...
BRAF V600E Dasatinib melanoma sensitive detail...
BRAF V600E Saracatinib melanoma sensitive detail...
BRAF V600E S3I-201 melanoma sensitive detail...
BRAF L505H BRAF V600E Vemurafenib melanoma predicted - resistant detail...
BRAF mut NRAS mut Lenvatinib melanoma sensitive detail...
BRAF V600E BI-69A11 melanoma sensitive detail...
BRAF V600E SBI-0640756 melanoma sensitive detail...
BRAF V600E SBI-0640726 melanoma sensitive detail...
NRAS mutant BI-69A11 melanoma sensitive detail...
NRAS mutant SBI-0640756 melanoma sensitive detail...
NRAS mutant SBI-0640726 melanoma sensitive detail...
BRAF V600E SBI-755199 melanoma sensitive detail...
BRAF V600E SBI-0640756 + Vemurafenib melanoma sensitive detail...
CDKN2A loss NRAS Q61K SBI-0640756 melanoma sensitive detail...
BRAF mut NRAS wild-type Lenvatinib melanoma sensitive detail...
BRAF wild-type NRAS mut Lenvatinib melanoma sensitive detail...
BRAF wild-type NRAS wild-type Lenvatinib melanoma sensitive detail...
BRAF V600E E6201 melanoma sensitive detail...
BRAF V600E MAP2K1 C121S E6201 melanoma sensitive detail...
BRAF V600E MAP2K1 C121S Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 C121S Selumetinib melanoma decreased response detail...
PTEN wild-type E6201 melanoma sensitive detail...
RB1 wild-type TP53 wild-type R547 melanoma sensitive detail...
PTEN dec exp Pembrolizumab melanoma decreased response detail...
PTEN dec exp Nivolumab melanoma decreased response detail...
PTEN positive Pembrolizumab melanoma sensitive detail...
PTEN positive Nivolumab melanoma sensitive detail...
PTEN loss GSK2636771 melanoma sensitive detail...
BRAF mut PTEN loss GSK2636771 + Pembrolizumab melanoma sensitive detail...
BRAF mut PTEN loss GSK2636771 melanoma no benefit detail...
BRAF mut PTEN loss Pembrolizumab melanoma no benefit detail...
BRAF V600E Navitoclax + Vemurafenib melanoma sensitive detail...
BRAF V600E Navitoclax + Trametinib melanoma sensitive detail...
BRAF V600E Trametinib + TW-37 melanoma sensitive detail...
BRAF V600E TW-37 + Vemurafenib melanoma sensitive detail...
NRAS mutant Tubastatin A melanoma sensitive detail...
BRAF mutant Tubastatin A melanoma sensitive detail...
BRAF V600E Cediranib + PLX4720 melanoma sensitive detail...
BRAF V600E PLX4720 + Selumetinib melanoma sensitive detail...
BRAF V600E Cediranib + PLX4720 + Selumetinib melanoma sensitive detail...
BRAF V600E PLX4720 + Tivozanib melanoma sensitive detail...
PTEN dec exp SAR260301 melanoma sensitive detail...
BRAF V600E BI 882370 + Trametinib melanoma sensitive detail...
BRAF V600E/K PIK3CA wild-type Selumetinib + Vemurafenib melanoma sensitive detail...
BRAF V600E/K PIK3CA wild-type Dactolisib + Vemurafenib melanoma sensitive detail...
BRAF V600E/K PIK3CA wild-type Vemurafenib + ZSTK474 melanoma sensitive detail...
BRAF V600E/K PIK3CA wild-type Selumetinib + ZSTK474 melanoma sensitive detail...
BRAF V600E/K PIK3CA wild-type Dactolisib + Selumetinib melanoma sensitive detail...
BRAF V600E/K PIK3CA wild-type A66 melanoma no benefit detail...
BRAF V600E/K PIK3CA wild-type TGX-221 melanoma no benefit detail...
BRAF V600E/K PIK3CA wild-type Idelalisib melanoma no benefit detail...
ALK wild-type Dalantercept + Doxorubicin melanoma sensitive detail...
BRAF V600E DEL-22379 melanoma sensitive detail...
BRAF mutant E6201 melanoma sensitive detail...
NRAS wild-type E6201 melanoma sensitive detail...
HRAS wild-type E6201 melanoma sensitive detail...
BRAF mutant E6201 + LY294002 melanoma sensitive detail...
BRAF mut PTEN mut E6201 melanoma decreased response detail...
BRAF mut PTEN wild-type E6201 melanoma sensitive detail...
BRAF V600E SCH772984 melanoma sensitive detail...
BRAF V600E PD-0325901 melanoma conflicting detail...
HRAS G12V CI-1040 melanoma sensitive detail...
BRAF V600E NRAS G12V Vemurafenib melanoma resistant detail...
BRAF V600E NRAS G12V DEL-22379 melanoma sensitive detail...
BRAF V600E MAP2K1 I103N PD-0325901 melanoma resistant detail...
BRAF V600E MAP2K1 L115P PD-0325901 melanoma resistant detail...
BRAF V600E MAP2K1 I103N DEL-22379 melanoma sensitive detail...
BRAF V600E MAP2K1 L115P DEL-22379 melanoma sensitive detail...
BRAF V600E MAP2K1 V211D CI-1040 melanoma resistant detail...
BRAF V600E MAP2K1 V211D Selumetinib melanoma resistant detail...
BRAF mutant Vemurafenib + Voruciclib melanoma sensitive detail...
BRAF V600E NRAS Q61K Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 P387S NRAS A146T Dabrafenib melanoma resistant detail...
BRAF V600E NRAS A146T Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 P387S NRAS Q61K Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 K59del Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 P387S NRAS Q61K NRAS A146T Dabrafenib melanoma resistant detail...
BRAF V600E NRAS A146T Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 P387S NRAS A146T Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 K59del Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 P387S NRAS Q61K NRAS A146T Vemurafenib melanoma resistant detail...
BRAF V600E NRAS A146T Trametinib melanoma decreased response detail...
BRAF V600E MAP2K1 P387S NRAS A146T Trametinib melanoma decreased response detail...
BRAF V600E MAP2K1 P387S NRAS Q61K Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 P387S NRAS Q61K Trametinib melanoma decreased response detail...
BRAF V600E MAP2K1 P387S NRAS Q61K NRAS A146T Trametinib melanoma resistant detail...
BRAF V600E MAP2K1 K59del Trametinib melanoma resistant detail...
BRAF V600E NRAS A146T GSK2126458 melanoma decreased response detail...
BRAF V600E MAP2K1 P387S NRAS A146T GSK2126458 melanoma decreased response detail...
BRAF V600E MAP2K1 P387S NRAS Q61K GSK2126458 melanoma decreased response detail...
BRAF V600E MAP2K1 P387S NRAS Q61K NRAS A146T GSK2126458 melanoma decreased response detail...
BRAF V600E MAP2K1 K59del GSK2126458 melanoma decreased response detail...
BRAF V600E GSK2126458 melanoma sensitive detail...
BRAF V600K NRAS Q61K Dabrafenib melanoma resistant detail...
BRAF V600K NRAS Q61K Trametinib melanoma decreased response detail...
BRAF V600K GSK2126458 melanoma sensitive detail...
BRAF V600K NRAS Q61K GSK2126458 melanoma predicted - sensitive detail...
BRAF V600E MAP2K1 Q56P Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 Q56P Trametinib melanoma conflicting detail...
BRAF V600E NRAS A146T Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E NRAS Q61K Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E NRAS Q61K NRAS A146T Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 K59del Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600K NRAS Q61K Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 Q56P Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 K59del Dabrafenib + GSK2126458 melanoma sensitive detail...
BRAF V600E MAP2K1 K59del GSK2126458 + Trametinib melanoma sensitive detail...
BRAF V600E GSK2126458 + Trametinib melanoma sensitive detail...
BRAF V600E Dabrafenib + GSK2126458 melanoma sensitive detail...
BRAF V600E Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E NRAS A146T Dabrafenib + GSK2126458 melanoma sensitive detail...
BRAF V600E MAP2K1 P387S NRAS A146T Dabrafenib + GSK2126458 melanoma no benefit detail...
BRAF V600E MAP2K1 P387S NRAS Q61K Dabrafenib + GSK2126458 melanoma conflicting detail...
BRAF V600E NRAS A146T GSK2126458 + Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 P387S NRAS A146T GSK2126458 + Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 P387S NRAS Q61K GSK2126458 + Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 P387S NRAS Q61K NRAS A146T GSK2126458 + Trametinib melanoma sensitive detail...
BRAF V600K NRAS Q61K GSK2126458 + Trametinib melanoma sensitive detail...
BRAF V600K NRAS Q61K Dabrafenib + GSK2126458 melanoma sensitive detail...
BRAF mut PTEN inact mut AZD6482 melanoma sensitive detail...
BRAF mut PTEN inact mut TGX-221 melanoma sensitive detail...
BRAF mut PTEN inact mut Pictilisib melanoma sensitive detail...
BRAF mut PTEN inact mut Alpelisib melanoma decreased response detail...
BRAF mut PTEN inact mut Alpelisib + AZD6482 melanoma sensitive detail...
BRAF mut PTEN inact mut Alpelisib + GSK2636771 melanoma sensitive detail...
BRAF mut PTEN inact mut AZD6482 + NVP-AEW541 melanoma sensitive detail...
BRAF mut PTEN inact mut GSK2636771 + NVP-AEW541 melanoma sensitive detail...
BRAF mut PTEN inact mut NVP-AEW541 + Pictilisib melanoma sensitive detail...
BRAF mut PTEN inact mut Alpelisib + NVP-AEW541 melanoma no benefit detail...
BRAF mut PTEN wild-type AZD6482 + NVP-AEW541 melanoma no benefit detail...
BRAF mut PTEN wild-type GSK2636771 + NVP-AEW541 melanoma no benefit detail...
BRAF mut PTEN inact mut Encorafenib + Pictilisib melanoma sensitive detail...
BRAF mut PTEN inact mut AZD6482 + Encorafenib melanoma sensitive detail...
BRAF mut PTEN inact mut Encorafenib + GSK2636771 melanoma sensitive detail...
BRAF mut PTEN inact mut Alpelisib + Encorafenib melanoma no benefit detail...
BRAF mut PTEN inact mut Binimetinib + Pictilisib melanoma sensitive detail...
BRAF mut PTEN inact mut AZD6482 + Binimetinib melanoma sensitive detail...
BRAF mut PTEN inact mut Binimetinib + GSK2636771 melanoma sensitive detail...
BRAF mut PTEN inact mut Alpelisib + Binimetinib melanoma no benefit detail...
BRAF mut PTEN wild-type AZD6482 + Binimetinib melanoma no benefit detail...
BRAF mut PTEN wild-type Binimetinib + GSK2636771 melanoma no benefit detail...
BRAF mut PTEN wild-type AZD6482 + Encorafenib melanoma no benefit detail...
BRAF mut PTEN wild-type Encorafenib + GSK2636771 melanoma no benefit detail...
BRAF mut PTEN inact mut Alpelisib + AZD6482 + Encorafenib melanoma sensitive detail...
BRAF mut PTEN inact mut AZD6482 + Encorafenib + NVP-AEW541 melanoma sensitive detail...
BRAF mut PTEN inact mut Alpelisib + AZD6482 + Binimetinib melanoma sensitive detail...
BRAF mut PTEN inact mut AZD6482 + Binimetinib + NVP-AEW541 melanoma sensitive detail...
BRAF mut PTEN inact mut AZD6482 + Binimetinib + Encorafenib + NVP-AEW541 melanoma sensitive detail...
BRAF mut PTEN inact mut Alpelisib + AZD6482 + Binimetinib + Encorafenib melanoma sensitive detail...
BRAF mut PTEN inact mut Alpelisib + Encorafenib + GSK2636771 melanoma sensitive detail...
BRAF mut PTEN inact mut GSK2636771 + unspecified IGF-1R antibody melanoma sensitive detail...
BRAF mut PTEN inact mut Encorafenib + unspecified IGF-1R antibody melanoma sensitive detail...
BRAF mut PTEN inact mut Encorafenib + GSK2636771 + unspecified IGF-1R antibody melanoma sensitive detail...
BRAF V600E PTEN loss XL147 melanoma sensitive detail...
BRAF V600D PTEN loss XL147 melanoma sensitive detail...
BRAF V600E LY3009120 melanoma sensitive detail...
NRAS Q61K LY3009120 melanoma sensitive detail...
BRAF G469R NRAS Q61K LY3009120 melanoma sensitive detail...
NRAS G13D LY3009120 melanoma sensitive detail...
NRAS Q61L LY3009120 melanoma decreased response detail...
TP53 D259Y LY3009120 melanoma sensitive detail...
NRAS Q61K Selumetinib melanoma sensitive detail...
NRAS G13D Selumetinib melanoma sensitive detail...
BRAF G469R NRAS Q61K Selumetinib melanoma decreased response detail...
NRAS Q61L Selumetinib melanoma decreased response detail...
TP53 D259Y Selumetinib melanoma sensitive detail...
TP53 D259Y Vemurafenib melanoma sensitive detail...
NRAS Q61K Vemurafenib melanoma resistant detail...
NRAS G13D Vemurafenib melanoma resistant detail...
NRAS Q61L Vemurafenib melanoma resistant detail...
BRAF G469R NRAS Q61K Vemurafenib melanoma resistant detail...
NRAS mutant Vemurafenib melanoma resistant detail...
NRAS mutant LY3009120 melanoma sensitive detail...
BRAF V600E DETD-35 melanoma sensitive detail...
BRAF V600E DETD-35 + Vemurafenib melanoma sensitive detail...
PTEN loss DETD-35 melanoma sensitive detail...
PTEN loss DETD-35 + Vemurafenib melanoma sensitive detail...
MAP2K1 V60E Trametinib melanoma resistant detail...
MAP2K1 V60E Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 H119P Selumetinib melanoma resistant detail...
BRAF V600E MAP2K1 V60E VX-11e melanoma sensitive detail...
BRAF V600E MAP2K1 C121S VX-11e melanoma sensitive detail...
BRAF V600E MAP2K1 P124S VX-11e melanoma sensitive detail...
BRAF V600E MAP2K1 G128V VX-11e melanoma sensitive detail...
BRAF V600E MAP2K1 P162S Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 P162S Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 P162S Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 C121S Dabrafenib + Trametinib melanoma resistant detail...
BRAF V600E MAP2K1 G128V Dabrafenib + Trametinib melanoma conflicting detail...
BRAF V600E MAP2K1 P124S Selumetinib melanoma decreased response detail...
BRAF V600E MAP2K1 C121S PLX4720 melanoma resistant detail...
BRAF V600E MAP2K1 V60E Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 P124S Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 G128V Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 G128V Trametinib melanoma resistant detail...
BRAF V600E MAP2K1 P124S Trametinib melanoma resistant detail...
BRAF V600X MAP2K1 V60E NRAS T58I NRAS Q61R Vemurafenib melanoma predicted - resistant detail...
BRAF V600X BRAF amp NRAS Q61K Vemurafenib melanoma resistant detail...
BRAF V600E PTEN loss Pictilisib + PLX4720 melanoma sensitive detail...
BRAF V600X PTEN H93D Vemurafenib melanoma predicted - sensitive detail...
BRAF V600E Lifirafenib melanoma sensitive detail...
JAK2 inact mut Pembrolizumab melanoma predicted - resistant detail...
BRAF V600E SHP099 melanoma no benefit detail...
BRAF V600E MAP2K1 K57E Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 P124Q Dabrafenib melanoma decreased response detail...
BRAF V600K MAP2K1 P124Q Dabrafenib melanoma decreased response detail...
BRAF V600K MAP2K1 P124L Dabrafenib melanoma decreased response detail...
BRAF V600K MAP2K1 P124L VX-11e melanoma sensitive detail...
BRAF V600K MAP2K1 P124Q VX-11e melanoma sensitive detail...
BRAF V600K MAP2K1 P124Q Trametinib melanoma sensitive detail...
BRAF V600K MAP2K1 P124L Trametinib melanoma sensitive detail...
KIT L576P Bevacizumab + Sorafenib melanoma predicted - sensitive detail...
BRAF mut PTEN loss SAR260301 melanoma sensitive detail...
BRAF mut PTEN loss SAR260301 + Vemurafenib melanoma sensitive detail...
BRAF mut PTEN loss SAR260301 + Selumetinib melanoma sensitive detail...
BRAF V600E BI-847325 melanoma sensitive detail...
BRAF mutant BI-847325 melanoma predicted - sensitive detail...
BRAF mut NRAS mut BI-847325 melanoma predicted - sensitive detail...
BRAF V600E PAC-1 + Vemurafenib melanoma sensitive detail...
BRAF V600E PAC-1 + Trametinib + Vemurafenib melanoma sensitive detail...
BRAF V600E GDC0879 melanoma sensitive detail...
BRAF wild-type NRAS Q61K GDC0879 melanoma resistant detail...
BRAF wild-type GDC0879 melanoma resistant detail...
BRAF V600E PTEN loss GDC0879 + Pictilisib melanoma sensitive detail...
BRAF V600E PLX7904 melanoma sensitive detail...
BRAF V600E AZ628 melanoma sensitive detail...
BRAF V600D AZ628 melanoma sensitive detail...
BRAF G466E AZ628 melanoma sensitive detail...
BRAF V600R AZ628 melanoma sensitive detail...
BRAF D594G NRAS G12D AZ628 melanoma sensitive detail...
BRAF wild-type NRAS wild-type AZ628 melanoma sensitive detail...
BRAF V600E TAK-632 melanoma sensitive detail...
BRAF V600D TAK-632 melanoma sensitive detail...
BRAF G466E TAK-632 melanoma sensitive detail...
BRAF V600R TAK-632 melanoma sensitive detail...
BRAF D594G NRAS G12D TAK-632 melanoma sensitive detail...
BRAF wild-type NRAS wild-type TAK-632 melanoma sensitive detail...
BRAF V600E SB590885 melanoma sensitive detail...
BRAF V600D PLX7904 melanoma sensitive detail...
BRAF G466E PLX7904 melanoma decreased response detail...
BRAF V600R PLX7904 melanoma sensitive detail...
BRAF D594G NRAS G12D PLX7904 melanoma decreased response detail...
BRAF wild-type NRAS wild-type PLX7904 melanoma resistant detail...
BRAF V600D Vemurafenib melanoma sensitive detail...
BRAF V600R Vemurafenib melanoma sensitive detail...
BRAF G466E Vemurafenib melanoma decreased response detail...
BRAF D594G NRAS G12D Vemurafenib melanoma decreased response detail...
BRAF wild-type NRAS wild-type Vemurafenib melanoma resistant detail...
BRAF V600D Dabrafenib melanoma sensitive detail...
BRAF V600R Dabrafenib melanoma sensitive detail...
BRAF G466E Dabrafenib melanoma decreased response detail...
BRAF D594G NRAS G12D Dabrafenib melanoma decreased response detail...
BRAF mut TP53 wild-type KRT-232 melanoma sensitive detail...
BRAF V600X Trametinib + Vemurafenib melanoma sensitive detail...
BRAF V600X Selumetinib + Vemurafenib melanoma sensitive detail...
BRAF V600X Buparlisib + Vemurafenib melanoma sensitive detail...
BRAF V600X Buparlisib + Trametinib melanoma sensitive detail...
BRAF V600X Buparlisib + Selumetinib melanoma sensitive detail...
BRAF V600X MK2206 + Vemurafenib melanoma sensitive detail...
BRAF V600X MK2206 + Trametinib melanoma sensitive detail...
BRAF V600X PTEN neg Uprosertib melanoma sensitive detail...
TP53 wild-type KRT-232 melanoma sensitive detail...
TP53 wild-type KRT-232 + Radiotherapy melanoma sensitive detail...
BRAF V600E RO4987655 melanoma sensitive detail...
BRAF V600E RO5126766 melanoma sensitive detail...
BRAF wild-type Palbociclib melanoma sensitive detail...
NRAS wild-type Palbociclib melanoma sensitive detail...
BRAF mut RB1 loss Palbociclib melanoma decreased response detail...
CDKN2A loss Palbociclib melanoma resistant detail...
NRAS wild-type Trametinib melanoma sensitive detail...
BRAF mut RB1 loss Trametinib melanoma decreased response detail...
CDKN2A loss Trametinib melanoma sensitive detail...
BRAF mutant Palbociclib + Trametinib melanoma sensitive detail...
BRAF wild-type Palbociclib + Trametinib melanoma decreased response detail...
NRAS wild-type Palbociclib + Trametinib melanoma decreased response detail...
BRAF mut RB1 loss Palbociclib + Trametinib melanoma decreased response detail...
BRAF V600E Palbociclib melanoma no benefit detail...
BRAF V600E Palbociclib + PD-0325901 melanoma sensitive detail...
NRAS mutant PD-0325901 melanoma no benefit detail...
NRAS mutant Palbociclib melanoma conflicting detail...
NRAS mutant Palbociclib + PD-0325901 melanoma sensitive detail...
KIT L576P Dasatinib melanoma sensitive detail...
KIT exon11 Imatinib melanoma predicted - sensitive detail...
KIT L576P Imatinib melanoma unknown detail...
KIT D820Y Sorafenib melanoma predicted - sensitive detail...
BRAF mutant S63845 + Trametinib melanoma sensitive detail...
NRAS mutant S63845 + Trametinib melanoma sensitive detail...
BRAF mutant S63845 + Vemurafenib melanoma sensitive detail...
BRAF V600E Imatinib + PLX4720 melanoma sensitive detail...
BRAF V600E Alpelisib + PLX4720 melanoma sensitive detail...
BRAF V600E PLX4720 + Vorinostat melanoma sensitive detail...
BRAF V600E Doxorubicin + PLX4720 melanoma sensitive detail...
BRAF V600E Erlotinib + PLX4720 melanoma sensitive detail...
BRAF mutant Binimetinib + Buparlisib melanoma sensitive detail...
NRAS mutant Binimetinib + Buparlisib melanoma sensitive detail...
BRAF wild-type NRAS wild-type Binimetinib + Buparlisib melanoma sensitive detail...
BRAF mutant Buparlisib + Encorafenib melanoma sensitive detail...
BRAF mutant Buparlisib melanoma sensitive detail...
NRAS mutant Buparlisib melanoma sensitive detail...
BRAF V600E PIK3CA H1047K Miransertib + Trametinib melanoma sensitive detail...
PTEN mutant BI-69A11 melanoma sensitive detail...
BRAF V600E MAP2K1 L115P CI-1040 melanoma resistant detail...
BRAF V600E MAP2K1 L115P Selumetinib melanoma resistant detail...
BRAF V600E MAP2K1 I103N Selumetinib melanoma resistant detail...
BRAF V600E MAP2K1 I103N CI-1040 melanoma resistant detail...
TP53 wild-type APR-246 melanoma sensitive detail...
BRAF V600E PTEN loss GSK2636771 + unspecified PD-1 antibody melanoma sensitive detail...
NRAS mutant Trametinib melanoma sensitive detail...
NRAS Q61L Binimetinib melanoma sensitive detail...
NRAS Q61K Binimetinib melanoma sensitive detail...
NRAS Q61R Binimetinib melanoma sensitive detail...
BRAF V600E ASN003 melanoma sensitive detail...
BRAF V600E PTEN mut ASN003 melanoma sensitive detail...
BRAF V600X ASN003 melanoma sensitive detail...
KIT D816V NRAS Q61R Pembrolizumab + Trametinib melanoma no benefit detail...
ATM mut NRAS Q61R Binimetinib melanoma predicted - sensitive detail...
BRAF V600X Dabrafenib + KRT-232 + Trametinib melanoma sensitive detail...
BRAF V600X Atezolizumab + Cobimetinib + Vemurafenib melanoma sensitive detail...
BRAF mutant PET-16 + Vemurafenib melanoma sensitive detail...
KIT exon11 Nilotinib melanoma sensitive detail...
KIT exon13 Nilotinib melanoma sensitive detail...
KIT L576P Nilotinib melanoma predicted - sensitive detail...
KIT W557R KIT L576P Nilotinib melanoma predicted - sensitive detail...
KIT K642E Nilotinib melanoma predicted - sensitive detail...
KIT V559D Nilotinib melanoma predicted - sensitive detail...
KIT V559A Nilotinib melanoma predicted - sensitive detail...
KIT V560D Nilotinib melanoma predicted - sensitive detail...
KIT W557R Nilotinib melanoma predicted - sensitive detail...
BRAF V600E Encorafenib + Ribociclib melanoma sensitive detail...
BRAF D594G Trametinib melanoma sensitive detail...
BRAF G466E HRAS Q61K Trametinib melanoma sensitive detail...
BRAF mutant KO-947 melanoma predicted - sensitive detail...
NRAS mutant KO-947 melanoma predicted - sensitive detail...
KIT V559A Imatinib melanoma predicted - sensitive detail...
BRAF V600E INU-152 melanoma sensitive detail...
BRAF K601E Trametinib melanoma predicted - sensitive detail...
BRAF K601E Dabrafenib melanoma no benefit detail...
BRAF V600E Cobimetinib melanoma predicted - sensitive detail...
BRAF mutant Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 I111N Trametinib melanoma resistant detail...
BRAF V600E MAP2K1 L115P Trametinib melanoma conflicting detail...
BRAF V600E MAP2K1 V211D Trametinib melanoma resistant detail...
BRAF V600E MAP2K1 I111N Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 L115P Vemurafenib melanoma conflicting detail...
BRAF V600E MAP2K1 V211D Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 V211D Ulixertinib melanoma sensitive detail...
BRAF V600E MAP2K1 C121S Trametinib melanoma conflicting detail...
BRAF V600E MAP2K1 E203K Trametinib melanoma conflicting detail...
BRAF V600E MAP2K1 E203K Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 P124L Trametinib melanoma decreased response detail...
BRAF V600E MAP2K1 P124L Vemurafenib melanoma predicted - resistant detail...
BRAF V600E MAP2K1 Q56P Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 Q56P Ulixertinib melanoma sensitive detail...
BRAF V600E MAP2K1 E203K Ulixertinib melanoma conflicting detail...
BRAF V600E EBI-907 melanoma sensitive detail...
BRAF V600E/K Cobimetinib + Vemurafenib melanoma sensitive detail...
BRAF V600E Cobimetinib + Vemurafenib melanoma sensitive detail...
BRAF V600K Cobimetinib + Vemurafenib melanoma sensitive detail...
BRAF mutant ST-162 melanoma predicted - sensitive detail...
BRAF mut PTEN mut ST-162 melanoma predicted - sensitive detail...
KIT D820Y Dasatinib melanoma sensitive detail...
KIT D820Y Imatinib melanoma resistant detail...
KIT D820Y SEL201 melanoma sensitive detail...
KIT L576P SEL201 melanoma sensitive detail...
BRAF V600E Dabrafenib + SCH772984 + Trametinib melanoma decreased response detail...
BRAF V600E RAF265 melanoma predicted - sensitive detail...
BRAF mutant Ulixertinib melanoma predicted - sensitive detail...
NRAS mutant Ulixertinib melanoma predicted - sensitive detail...
BRAF V600K Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E Trametinib melanoma sensitive detail...
BRAF V600K Trametinib melanoma sensitive detail...
BRAF V600E RAF709 melanoma sensitive detail...
NRAS Q61K RAF709 melanoma predicted - sensitive detail...
NRAS Q61L RAF709 melanoma sensitive detail...
BRAF V600E/K Binimetinib + Encorafenib melanoma sensitive detail...
NRAS mutant Belvarafenib melanoma predicted - sensitive detail...
BRAF L514V BRAF V600E Vemurafenib melanoma decreased response detail...
BRAF L514V BRAF V600E Dabrafenib melanoma decreased response detail...
BRAF L514V BRAF V600E PLX8394 melanoma decreased response detail...
BRAF L514V BRAF V600E TAK-632 melanoma decreased response detail...
BRAF L514V BRAF V600E BGB3245 melanoma predicted - sensitive detail...
BRAF L514V BRAF V600E BGB3290 melanoma predicted - sensitive detail...
BRAF L514V BRAF V600E SCH772984 melanoma predicted - sensitive detail...
BRAF L514V BRAF V600E Trametinib melanoma decreased response detail...
BRAF L597S Encorafenib melanoma sensitive detail...
BRAF G469V Encorafenib melanoma no benefit detail...
BRAF G469V NRAS Q61K Encorafenib + Trametinib melanoma sensitive detail...
BRAF G469V NRAS Q61K Binimetinib + Encorafenib melanoma sensitive detail...
BRAF L597S Binimetinib + Encorafenib melanoma sensitive detail...
BRAF L597S Encorafenib + Trametinib melanoma sensitive detail...
BRAF G469V NRAS Q61K Trametinib + Vemurafenib melanoma predicted - resistant detail...
BRAF G469V NRAS Q61K LY3009120 melanoma sensitive detail...
BRAF L597S LY3009120 melanoma sensitive detail...
BRAF L597S Dabrafenib melanoma predicted - sensitive detail...
BRAF G469V NRAS Q61K Dabrafenib melanoma no benefit detail...
BRAF R239Q BRAF L597S Binimetinib + Encorafenib melanoma sensitive detail...
BRAF R239Q BRAF L597S Encorafenib melanoma sensitive detail...
BRAF R239Q BRAF L597S Binimetinib melanoma sensitive detail...
BRAF L597S Dabrafenib + Trametinib melanoma sensitive detail...
BRAF R239Q BRAF L597S Dabrafenib + Trametinib melanoma sensitive detail...
BRAF S363F BRAF K601E Encorafenib + Trametinib melanoma sensitive detail...
BRAF S363F BRAF K601E Encorafenib melanoma sensitive detail...
BRAF S363F BRAF K601E Dabrafenib + Trametinib melanoma sensitive detail...
BRAF S363F BRAF K601E Trametinib + Vemurafenib melanoma sensitive detail...
BRAF L597S Trametinib melanoma predicted - sensitive detail...
BRAF S363F BRAF K601E Trametinib melanoma sensitive detail...
BRAF L597S Cobimetinib melanoma sensitive detail...
BRAF S363F BRAF K601E Cobimetinib melanoma sensitive detail...
BRAF S363F BRAF K601E Binimetinib melanoma sensitive detail...
BRAF L597S Binimetinib melanoma sensitive detail...
BRAF V600E Ulixertinib melanoma sensitive detail...
BRAF V600K Pembrolizumab melanoma predicted - sensitive detail...
BRAF V600K Nivolumab melanoma predicted - sensitive detail...
BRAF V600E Nivolumab melanoma decreased response detail...
BRAF V600E Pembrolizumab melanoma decreased response detail...
BRAF V600E/K Vemurafenib + XL888 melanoma predicted - sensitive detail...
BRAF V600E RMC-4550 melanoma resistant detail...
NRAS over exp Binimetinib melanoma predicted - sensitive detail...
BRAF V600D NRAS dec exp Binimetinib melanoma no benefit detail...
NRAS amp Binimetinib melanoma predicted - sensitive detail...
BRAF wild-type Nivolumab melanoma predicted - sensitive detail...
BRAF V47_D380del Dabrafenib + Trametinib melanoma predicted - resistant detail...
BRAF V600E Binimetinib + Encorafenib melanoma sensitive detail...
BRAF V600K Binimetinib + Encorafenib melanoma sensitive detail...
NRAS mutant Palbociclib + Trametinib melanoma predicted - sensitive detail...
NRAS mut PIK3CA E545K Palbociclib + Trametinib melanoma predicted - resistant detail...
NRAS mut PIK3CA H1047R Trametinib melanoma predicted - resistant detail...
NRAS mut PIK3CA E545K Trametinib melanoma predicted - resistant detail...
BRAF mutant Belvarafenib melanoma predicted - sensitive detail...
KIT T632I Imatinib melanoma predicted - resistant detail...
NRAS mut PIK3CA E545K Palbociclib melanoma predicted - resistant detail...
NRAS Q61L NRAS mut Trametinib melanoma predicted - resistant detail...
NRAS Q61L NRAS mut Palbociclib + Trametinib melanoma predicted - resistant detail...
NRAS Q61L NRAS mut Palbociclib melanoma decreased response detail...
NRAS Q61K NRAS mut Trametinib melanoma predicted - resistant detail...
NRAS Q61K NRAS mut Palbociclib + Trametinib melanoma predicted - resistant detail...
NRAS Q61K NRAS mut Palbociclib melanoma decreased response detail...
NRAS mutant Pembrolizumab melanoma predicted - sensitive detail...
NRAS mutant Nivolumab melanoma predicted - sensitive detail...
BRAF V600X Atezolizumab + Vemurafenib melanoma sensitive detail...
BRAF V600E PTEN loss unspecified PD-1 antibody + VE800 melanoma sensitive detail...
BRAF V47_D380del BRAF V600E Vemurafenib melanoma resistant detail...
BRAF mutant UNC2025 + Vemurafenib melanoma predicted - sensitive detail...
NRAS mutant Cobimetinib + UNC2025 melanoma predicted - sensitive detail...
BRAF V600E PTEN Y27C Vemurafenib melanoma predicted - resistant detail...
BRAF V600K MAP2K1 P124L Dabrafenib + Trametinib melanoma predicted - resistant detail...
BRAF V600E PTEN del Dabrafenib melanoma predicted - resistant detail...
KIT V559X KIT N822I Imatinib + Pembrolizumab melanoma predicted - sensitive detail...
ARID1A mutant unspecified PD-1 antibody melanoma predicted - sensitive detail...
ARID1A mutant unspecified PD-L1 antibody melanoma predicted - sensitive detail...
BRAF V600E Dabrafenib + Pembrolizumab + Trametinib melanoma predicted - sensitive detail...
BRAF V600K Dabrafenib + Pembrolizumab + Trametinib melanoma predicted - sensitive detail...
BRAF V600E MAP2K1 I99T Trametinib melanoma resistant detail...
BRAF V600E MAP2K1 I99G Trametinib melanoma resistant detail...
BRAF V600E MAP2K1 I99M Trametinib melanoma sensitive detail...
BRAF L485S BRAF V600E Dabrafenib melanoma resistant detail...
BRAF V600E PIK3CA H1047R PTEN Y68fs Vemurafenib melanoma predicted - resistant detail...
ARID1A inact mut unspecified immune checkpoint inhibitor melanoma not predictive detail...
BRAF V600E/K Lifirafenib melanoma predicted - sensitive detail...
FBXW7 R505C unspecified PD-1 antibody melanoma predicted - resistant detail...
FBXW7 loss unspecified PD-1 antibody melanoma predicted - resistant detail...
FBXW7 R505C Pembrolizumab melanoma predicted - resistant detail...
BRAF V600E BRAF V600M Dabrafenib melanoma predicted - sensitive detail...
BRAF V600X Dabrafenib + Spartalizumab + Trametinib melanoma predicted - sensitive detail...
NRAS Q61R Chelidonine melanoma sensitive detail...
NRAS Q61K Chelidonine melanoma sensitive detail...
NRAS Q61L Chelidonine melanoma sensitive detail...
BRAF L597R Sorafenib melanoma predicted - sensitive detail...
BRAF L597R Dabrafenib melanoma predicted - sensitive detail...
BRAF L597R Vemurafenib melanoma predicted - sensitive detail...
BRAF wild-type Vemurafenib melanoma no benefit detail...
BRAF wild-type Sorafenib melanoma predicted - sensitive detail...
BRAF G469E Sorafenib melanoma sensitive detail...
BRAF K601E Sorafenib melanoma predicted - sensitive detail...
BRAF D594G Sorafenib melanoma sensitive detail...
BRAF K601E U0126 melanoma predicted - sensitive detail...
BRAF V600E U0126 melanoma predicted - sensitive detail...
BRAF D594G U0126 melanoma resistant detail...
BRAF G469E U0126 melanoma resistant detail...
BRAF V600E C6-ceramide nanoliposome + Sorafenib melanoma sensitive detail...
NRAS Q61K UCM-1336 melanoma predicted - sensitive detail...
BRAF V600E BGB659 melanoma sensitive detail...
NRAS Q61R LY3009120 melanoma predicted - sensitive detail...
NRAS Q61R BGB659 melanoma predicted - sensitive detail...
NRAS Q61R TAK-632 melanoma predicted - sensitive detail...
BRAF V600E PLX8394 melanoma sensitive detail...
NRAS Q61R PLX8394 melanoma resistant detail...
BRAF G469A PLX8394 melanoma sensitive detail...
BRAF V600E BRAF over exp PLX8394 melanoma sensitive detail...
BRAF V600E BRAF over exp Vemurafenib melanoma resistant detail...
NRAS Q61K PLX8394 melanoma resistant detail...
BRAF V600E BI-3406 melanoma predicted - resistant detail...
BRAF V600E AZD0364 melanoma sensitive detail...
BRAF V600E MAP2K1 Q56P NRAS Q61R AZD0364 melanoma sensitive detail...
NRAS Q61R Chloroquine + Trametinib melanoma sensitive detail...
NRAS mutant Chloroquine + Trametinib melanoma sensitive detail...
BRAF V600E Lifirafenib + Trametinib melanoma sensitive detail...
NRAS Q61R Lifirafenib + Trametinib melanoma sensitive detail...
NRAS G13D Lifirafenib + Trametinib melanoma sensitive detail...
NRAS Q61K Lifirafenib + SCH772984 melanoma decreased response detail...
NRAS Q61L Lifirafenib + SCH772984 melanoma decreased response detail...
NRAS Q61R Lifirafenib + SCH772984 melanoma decreased response detail...
NRAS Q61K Lifirafenib + Vemurafenib melanoma decreased response detail...
NRAS Q61L Lifirafenib + Vemurafenib melanoma decreased response detail...
NRAS Q61K Lifirafenib + Ulixertinib melanoma no benefit detail...
NRAS Q61K Lifirafenib + MK-8353 melanoma no benefit detail...
NRAS Q61L Lifirafenib + Ulixertinib melanoma no benefit detail...
NRAS Q61L Lifirafenib + MK-8353 melanoma no benefit detail...
NRAS Q61K Binimetinib + RAF709 melanoma sensitive detail...
NRAS Q61L Binimetinib + RAF709 melanoma sensitive detail...
NRAS Q61R Binimetinib + RAF709 melanoma sensitive detail...
BRAF V600E Dabrafenib + Regorafenib + Trametinib melanoma sensitive detail...
BRAF V600E Dabrafenib + LXH 254 + Trametinib melanoma sensitive detail...
BRAF V600E Dabrafenib + RAF709 + Trametinib melanoma sensitive detail...
BRAF V600E LXH 254 melanoma predicted - sensitive detail...
BRAF D287H NRAS Q61K LXH 254 melanoma predicted - sensitive detail...
BRAF loss NRAS Q61K LXH 254 melanoma decreased response detail...
BRAF V600E JSI-1187 melanoma predicted - sensitive detail...
BRAF V600E RM-018 melanoma no benefit detail...
NRAS mutant Belvarafenib + Cobimetinib melanoma predicted - sensitive detail...
BRAF G469S Binimetinib + Encorafenib melanoma predicted - sensitive detail...
BRAF V600X Binimetinib + Encorafenib + Pembrolizumab melanoma predicted - sensitive detail...
BRAF V600X Dabrafenib + Nivolumab + Trametinib melanoma predicted - sensitive detail...
BRAF V600E Cobimetinib + Pembrolizumab + Vemurafenib melanoma no benefit detail...
BRAF V600K Cobimetinib + Pembrolizumab + Vemurafenib melanoma no benefit detail...
BRAF V600D Belvarafenib + Cobimetinib melanoma sensitive detail...
NRAS Q61L Belvarafenib + Cobimetinib melanoma sensitive detail...
NRAS Q61K Belvarafenib melanoma predicted - sensitive detail...
BRAF V600E Belvarafenib melanoma predicted - sensitive detail...
BRAF G534D NRAS Q61L Belvarafenib melanoma resistant detail...
NRAS Q61R Belvarafenib melanoma predicted - sensitive detail...
NRAS Q61L LY3214996 melanoma predicted - sensitive detail...
BRAF V600E LY3214996 melanoma sensitive detail...
BRAF V600E/K CDKN2A loss RB1 pos Palbociclib + Vemurafenib melanoma predicted - sensitive detail...
BRAF V600E CDKN2A loss CHEK2 dec exp RB1 pos Palbociclib + Vemurafenib melanoma predicted - resistant detail...
BRAF V600E ERAS-007 melanoma sensitive detail...
NRAS Q61R ERAS-007 melanoma sensitive detail...
BRAF V600E CDKN2A loss NRAS Q61K Cobimetinib + Vemurafenib melanoma predicted - resistant detail...
BRAF V600E CDKN2A loss NRAS G12V Cobimetinib + Vemurafenib melanoma predicted - resistant detail...
BRAF V600E CDKN2A loss NRAS G12V Palbociclib + Trametinib melanoma predicted - sensitive detail...
BRAF V600E CDKN2A loss NRAS G12V Palbociclib + Ulixertinib melanoma predicted - sensitive detail...
JAK2 loss VSV-delta51 melanoma sensitive detail...
JAK2 LOH JAK2 inact mut VSV-delta51 melanoma predicted - sensitive detail...
JAK2 LOH JAK2 inact mut HSV1-dICP0 melanoma predicted - sensitive detail...
JAK2 dec exp VSV-delta51 melanoma predicted - sensitive detail...
BRAF I463W BRAF V600E Dabrafenib melanoma resistant detail...
CDKN2A inact mut unspecified immune checkpoint inhibitor melanoma decreased response detail...
CDKN2A del unspecified immune checkpoint inhibitor melanoma decreased response detail...
BRAF V600E MAP2K1 S218D MAP2K1 S222D Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 I99T Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 I99G Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 I99M Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 L115R CI-1040 melanoma resistant detail...
BRAF V600E MAP2K1 L115R Selumetinib melanoma resistant detail...
BRAF V600E MAP2K1 L115R PLX4720 melanoma resistant detail...
BRAF V600E MAP2K1 P124L PLX4720 melanoma resistant detail...
BRAF V600E MAP2K1 I99T CI-1040 melanoma resistant detail...
BRAF V600E MAP2K1 I99T Selumetinib melanoma resistant detail...
BRAF V600E MAP2K1 I111N Selumetinib melanoma resistant detail...
BRAF V600E MAP2K1 I111N CI-1040 melanoma resistant detail...
BRAF V600E MAP2K1 H119P CI-1040 melanoma resistant detail...
BRAF V600E KRT-232 melanoma predicted - resistant detail...
BRAF V600E Dabrafenib + KRT-232 + Trametinib melanoma predicted - sensitive detail...
BRAF V600E KRT-232 + Navitoclax melanoma sensitive detail...
BRAF V600E ASTX029 melanoma sensitive detail...
BRAF V600E NRAS Q61K ASTX029 melanoma sensitive detail...
BRAF V600E ASTX029 + Vemurafenib melanoma sensitive detail...
NRAS Q61R ASTX029 melanoma sensitive detail...
NRAS Q61K ASTX029 melanoma sensitive detail...
BRAF V600D ASTX029 melanoma sensitive detail...
NRAS G12D ASTX029 melanoma sensitive detail...
NRAS G13D ASTX029 melanoma sensitive detail...
BRAF N486_P490del Cobimetinib melanoma sensitive detail...
BRAF N486_P490del PD-0325901 melanoma sensitive detail...
BRAF N486_P490del GDC0879 melanoma predicted - sensitive detail...
BRAF N486_P490del AZ628 melanoma sensitive detail...
BRAF N486_P490del Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 F53S Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 D67N Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 Y134C Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 P264L Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 F53S Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 Y134C Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 D67N Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 P264L Trametinib melanoma sensitive detail...
BRAF V600E NRAS Q61L Vemurafenib melanoma resistant detail...
KIT mutant Ripretinib melanoma predicted - sensitive detail...
BRAF class 1 Exarafenib melanoma predicted - sensitive detail...
BRAF class 3 Exarafenib melanoma predicted - sensitive detail...
BRAF V600K MAP2K1 P124S Dabrafenib melanoma predicted - resistant detail...
BRAF L597K Cobimetinib + Vemurafenib melanoma predicted - sensitive detail...
BRAF mutant unspecified PD-1 antibody melanoma predicted - sensitive detail...
BRAF T599dup Binimetinib + Encorafenib melanoma predicted - sensitive detail...
BRAF T599dup Dabrafenib + Trametinib melanoma predicted - sensitive detail...
BRAF T599dup Vemurafenib melanoma predicted - resistant detail...
NRAS Q61X Binimetinib + Ribociclib melanoma sensitive detail...
BRAF D594G Ulixertinib melanoma predicted - sensitive detail...
NRAS act mut Binimetinib + Ribociclib melanoma predicted - sensitive detail...
BRAF G469A BRAF L584P Dabrafenib + Trametinib melanoma predicted - sensitive detail...
BRAF D594G NRAS G12D Binimetinib + Encorafenib melanoma sensitive detail...
BRAF K601E Dabrafenib + Trametinib melanoma predicted - sensitive detail...
BRAF K601E Vemurafenib melanoma no benefit detail...
BRAF V600E PF-07284890 melanoma predicted - sensitive detail...
NRAS act mut Binimetinib + Exarafenib melanoma predicted - sensitive detail...
NRAS Q61R IMM-1-104 melanoma predicted - sensitive detail...
BRAF V600E IMM-1-104 melanoma predicted - sensitive detail...
NRAS mutant LXH 254 + Trametinib melanoma predicted - sensitive detail...
KIT L576P Ripretinib melanoma predicted - sensitive detail...
KIT D820Y Ripretinib melanoma predicted - sensitive detail...
KIT Y823D Ripretinib melanoma predicted - sensitive detail...
KIT V560D KIT D579G KIT D816N Ripretinib melanoma predicted - sensitive detail...
BRAF V600E Abemaciclib melanoma predicted - sensitive detail...
NRAS mutant LTT462 + LXH 254 melanoma predicted - sensitive detail...
NRAS act mut FCN-159 melanoma predicted - sensitive detail...
BRAF act mut Ipilimumab + Nivolumab melanoma predicted - sensitive detail...
BRAF T470R Trametinib melanoma predicted - sensitive detail...
BRAF L597Q Trametinib melanoma predicted - sensitive detail...
BRAF A598_T599insV Trametinib melanoma predicted - sensitive detail...
NRAS Q61R PD-0325901 melanoma sensitive detail...
NRAS Q61R RO5126766 melanoma sensitive detail...
NRAS G13R Binimetinib + Ribociclib melanoma predicted - sensitive detail...
NRAS G13R PIK3CA E545K Binimetinib + Ribociclib melanoma predicted - resistant detail...
NRAS Q61L Binimetinib + Ribociclib melanoma sensitive detail...
NRAS Q61K Binimetinib + Ribociclib melanoma sensitive detail...
NRAS Q61L PIK3CA E545K Binimetinib + Ribociclib melanoma predicted - resistant detail...
NRAS Q61K PIK3CA E545K Binimetinib + Ribociclib melanoma predicted - resistant detail...
NRAS Q61K PIK3CA E545K Ribociclib melanoma predicted - sensitive detail...
NRAS Q61L PIK3CA E545K Ribociclib melanoma predicted - resistant detail...
NRAS Q61L PIK3CA E545K Binimetinib melanoma predicted - resistant detail...
NRAS Q61K PIK3CA E545K Binimetinib melanoma predicted - resistant detail...
NRAS Q61L PIK3CA E545K Binimetinib + PF-4708671 + Ribociclib melanoma predicted - sensitive detail...
NRAS Q61K PIK3CA E545K Binimetinib + PF-4708671 + Ribociclib melanoma predicted - sensitive detail...
NRAS Q61L PIK3CA E545K Binimetinib + Ribociclib + Sirolimus melanoma predicted - sensitive detail...
NRAS Q61K PIK3CA E545K Binimetinib + Ribociclib + Sirolimus melanoma predicted - sensitive detail...
BRAF A598_T599insV Dabrafenib + Trametinib melanoma predicted - sensitive detail...
BRAF V600R Dabrafenib + Trametinib melanoma predicted - sensitive detail...
BRAF G469S Dabrafenib + Trametinib melanoma predicted - sensitive detail...
BRAF N581S NRAS Q61R Dabrafenib + Trametinib melanoma predicted - sensitive detail...
BRAF V600E MAP2K1 K4N Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 A14S Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 R49H Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 S72G Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 A76V Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 G79V Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 S86A Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 V93F Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 M94I Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 R96K Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 A106T Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 R108Q Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 A132V Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 Y134C Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 D136N Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 M146I Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 S150F Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 V154I Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 P162S Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 V224M Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 L235H Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 W247* Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 V258I Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 P264S Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 G294E Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 P306H Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 S200Y Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 Y229H Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 S231L Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 R291K Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 P293S Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 I310L Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 P326H Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 S327T Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 S331R Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 D336H Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 N345T Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 R201H Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 R201C Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 S212N Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 R349K Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 E367K Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 N382H Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 P387S Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 K4N Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 A14S Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 R47Q Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 R49C Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 R49H Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 R49L Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 S72G Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 A76V Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 G79V Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 S86A Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 V93F Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 M94I Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 R96K Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 A106T Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 R108Q Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 V127M Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 A132V Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 D136N Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 M146I Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 S150F Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 V154I Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 G176S Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 P193S Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 S200Y Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 R201C Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 R201H Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 S212N Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 L215F Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 Y229H Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 S231L Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 L235H Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 W247* Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 V258I Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 P264S Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 R291K Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 P293S Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 G294E Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 P306H Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 P326H Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 S327T Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 S331R Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 D336H Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 N345T Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 R349K Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 D351G Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 E367K Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 N382H Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 P387S Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 K4N Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 A14S Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 R47Q Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 R49C Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 R49H Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 S72G Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 A76V Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 G79V Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 S86A Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 V93F Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 M94I Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 R96K Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 A106T Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 R108Q Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 V127M Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 A132V Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 Y134C Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 D136N Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 M146I Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 S150F Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 V154I Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 P162S Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 G176S Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 P193S Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 S200Y Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 R201C Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 R201H Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 S212N Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 L215F Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 Y229H Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 S231L Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 L235H Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 W247* Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 V258I Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 P264S Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 R291K Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 P293S Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 G294E Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 P306H Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 I310L Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 P326H Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 S327T Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 S331R Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 D336H Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 N345T Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 R349K Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 D351G Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 E367K Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 N382H Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 P387S Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 K4N Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 R49H Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 S72G Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 A76V Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 G79V Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 S86A Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 V93F Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 R108Q Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 V127M Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 A132V Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 D136N Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 M146I Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 S150F Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 V154I Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 P162S Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 G176S Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 R201C Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 R201H Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 S212N Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 L215F Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 V224M Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 Y229H Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 S231L Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 L235H Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 W247* Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 V258I Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 P264S Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 R291K Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 P293S Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 G294E Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 P306H Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 I310L Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 P326H Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 S327T Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 S331R Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 D336H Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 N345T Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 R349K Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 N382H Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 K4N Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 A14S Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 R47Q Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 R49H Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 S72G Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 A76V Dabrafenib melanoma sensitive detail...
BRAF L485_P490del Dabrafenib + Trametinib melanoma predicted - sensitive detail...
BRAF V600E MAP2K1 G79V Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 V93F Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 R96K Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 M94I Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 A106T Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 R108Q Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 V127M Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 A132V Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 Y134C Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 D136N Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 M146I Dabrafenib melanoma sensitive detail...
BRAF L597X Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 S150F Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 V154I Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 G176S Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 P193S Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 S200Y Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 R201C Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 R201H Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 S212N Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 L215F Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 Y229H Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 S231L Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 L235H Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 W247* Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 V258I Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 P264S Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 R291K Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 P293S Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 G294E Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 P306H Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 P326H Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 S327T Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 S331R Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 D336H Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 N345T Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 R349K Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 D351G Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 E367K Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 N382H Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 P387S Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 K4N Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 A14S Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 R47Q Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 R49C Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 R49H Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 S72G Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 A76V Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 G79V Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 S86A Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 V93F Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 M94I Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 R96K Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 A106T Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 R108Q Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 V127M Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 A132V Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 Y134C Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 D136N Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 M146I Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 S150F Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 V154I Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 P162S Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 G176S Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 P193S Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 S200Y Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 R201C Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 R201H Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 S212N Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 L215F Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 Y229H Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 S231L Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 L235H Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 W247* Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 V258I Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 P264S Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 R291K Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 P293S Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 G294E Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 P306H Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 I310L Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 P326H Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 S327T Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 S331R Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 D336H Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 N345T Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 R349K Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 D351G Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 E367K Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 N382H Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 P387S Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 R49L Cobimetinib + Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 F53_Q58delinsL Cobimetinib melanoma resistant detail...
BRAF V600E MAP2K1 F53I Cobimetinib melanoma resistant detail...
BRAF V600E MAP2K1 K57E Cobimetinib melanoma resistant detail...
BRAF V600E MAP2K1 K57N Cobimetinib melanoma resistant detail...
BRAF V600E MAP2K1 K57T Cobimetinib melanoma resistant detail...
BRAF V600E MAP2K1 I99_K104del Cobimetinib melanoma resistant detail...
BRAF V600E MAP2K1 L115P Cobimetinib melanoma resistant detail...
BRAF V600E MAP2K1 E203K Cobimetinib melanoma resistant detail...
BRAF V600E MAP2K1 F53_Q58delinsL Trametinib melanoma resistant detail...
BRAF V600E MAP2K1 L54P Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 K57_G61del Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 Q58_E62del Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 G61_D65del Trametinib melanoma sensitive detail...
NRAS act mut Tunlametinib melanoma predicted - sensitive detail...
BRAF V600E MAP2K1 L63_D67del Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 D67Y Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 I99_K104del Trametinib melanoma resistant detail...
BRAF V600E MAP2K1 I111S Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 I204T Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 F53_Q58delinsL Binimetinib melanoma resistant detail...
BRAF V600E MAP2K1 K57T Binimetinib melanoma resistant detail...
BRAF V600E MAP2K1 L63_D67del Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 D67Y Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 I99_K104del Binimetinib melanoma resistant detail...
BRAF V600E MAP2K1 E102_I103del Binimetinib melanoma resistant detail...
BRAF V600E MAP2K1 P105_A106del Binimetinib melanoma resistant detail...
BRAF V600E MAP2K1 L115P Binimetinib melanoma resistant detail...
NRAS Q61R Tunlametinib melanoma predicted - sensitive detail...
NRAS G12S Tunlametinib melanoma predicted - sensitive detail...
BRAF V600E MAP2K1 C121S Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 F53_Q58delinsL Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 F53C Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 F53I Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 F53L Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 F53V Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 F53Y Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 K57E Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 K57N Vemurafenib melanoma resistant detail...
BRAF V600E PTEN loss Dabrafenib + Enzalutamide + Trametinib melanoma predicted - sensitive detail...
BRAF V600E MAP2K1 K57T Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 Q58_E62del Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 V60E Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 L63_D67del Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 I99_K104del Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 E102_I103del Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 I103_K104del Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 I103N Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 P105_A106del Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 P124S Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 G128D Vemurafenib melanoma resistant detail...
BRAF V600E DS03090629 melanoma predicted - sensitive detail...
BRAF V600E Dabrafenib + DS03090629 melanoma sensitive detail...
BRAF V600E BRAF over exp Trametinib melanoma resistant detail...
BRAF V600E BRAF over exp Dabrafenib melanoma resistant detail...
BRAF V600E BRAF over exp Dabrafenib + Trametinib melanoma resistant detail...
BRAF V600E BRAF over exp DS03090629 melanoma predicted - sensitive detail...
BRAF V600E BRAF over exp Dabrafenib + DS03090629 melanoma sensitive detail...
BRAF V600E MAP2K1 F53L Trametinib melanoma conflicting detail...
BRAF V600E MAP2K1 F53L Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 F53L DS03090629 melanoma sensitive detail...
BRAF V600E NRAS Q61K Trametinib melanoma resistant detail...
BRAF V600E NRAS Q61K DS03090629 melanoma predicted - resistant detail...
BRAF V600E MAP2K1 E203V Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 F53_Q58delinsL Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 F53C Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 F53I Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 F53V Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 K57T Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 Q58_E62del Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 L63_D67del Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 I99_K104del Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 E102_I103del Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 I103_K104del Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 I103N Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 P105_A106del Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 I111S Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 C121S Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 G128D Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 E203K Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 F53_Q58delinsL Encorafenib melanoma resistant detail...
BRAF V600E MAP2K1 F53C Encorafenib melanoma resistant detail...
BRAF V600E MAP2K1 F53I Encorafenib melanoma resistant detail...
MAP2K1 C121S MAP2K1 P124R Trametinib melanoma predicted - sensitive detail...
BRAF V600E MAP2K1 F53L Encorafenib melanoma resistant detail...
BRAF V600E MAP2K1 F53V Encorafenib melanoma resistant detail...
BRAF V600E MAP2K1 K57E Encorafenib melanoma resistant detail...
BRAF V600E MAP2K1 K57T Encorafenib melanoma resistant detail...
BRAF V600E MAP2K1 V60E Encorafenib melanoma resistant detail...
BRAF V600E MAP2K1 L63_D67del Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 I99_K104del Encorafenib melanoma resistant detail...
BRAF V600E MAP2K1 E102_I103del Encorafenib melanoma resistant detail...
BRAF V600E MAP2K1 I103_K104del Encorafenib melanoma resistant detail...
BRAF V600E MAP2K1 I103N Encorafenib melanoma resistant detail...
BRAF V600E MAP2K1 P105_A106del Encorafenib melanoma resistant detail...
BRAF V600E MAP2K1 L115P Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 C121S Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 E203K Encorafenib melanoma resistant detail...
BRAF V600E MAP2K1 F53I Cobimetinib + Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 K57E Cobimetinib + Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 K57N Cobimetinib + Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 Q58* Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 Q58* Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 Q58* Binimetinib melanoma sensitive detail...
BRAF wild-type Atezolizumab + Cobimetinib melanoma no benefit detail...
BRAF V600E MAP2K1 Q58* Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 Q58* Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 Q58* Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 K57T Cobimetinib + Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 E102_I103del Cobimetinib + Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 I103N Cobimetinib + Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 P124L Cobimetinib + Vemurafenib melanoma sensitive detail...
BRAF V600X Ipilimumab + Nivolumab melanoma predicted - sensitive detail...
BRAF V600E MAP2K1 P124S Cobimetinib + Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 G128D Cobimetinib + Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 E203K Cobimetinib + Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 E203V Cobimetinib + Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 F53_Q58delinsL Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 F53C Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 F53I Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 F53L Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 F53V Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 F53Y Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 K57E Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 K57T Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 V60E Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 D67N Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 E102_I103del Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 I103_K104del Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 I103N Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 P105_A106del Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 H119Y Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 P124Q Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 G128D Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 F129L Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 E203K Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 E203V Dabrafenib + Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 F53_Q58delinsL Binimetinib + Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 F53C Binimetinib + Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 F53I Binimetinib + Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 F53L Binimetinib + Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 F53V Binimetinib + Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 F53Y Binimetinib + Encorafenib melanoma sensitive detail...
MAP2K1 K57E Binimetinib + Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 K57T Binimetinib + Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 V60E Binimetinib + Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 D67N Binimetinib + Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 E102_I103del Binimetinib + Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 I103N Binimetinib + Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 P105_A106del Binimetinib + Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 H119Y Binimetinib + Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 P124Q Binimetinib + Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 P124S Binimetinib + Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 F129L Binimetinib + Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 E203K Binimetinib + Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 E203V Binimetinib + Encorafenib melanoma sensitive detail...
BRAF V600X Dabrafenib + Hydroxychloroquine + Trametinib melanoma predicted - sensitive detail...
NRAS mutant BDTX-4933 melanoma predicted - sensitive detail...
BRAF V600E MAP2K1 Q56_G61delinsR Cobimetinib melanoma resistant detail...
BRAF V600E MAP2K1 Q56_G61delinsR Trametinib melanoma resistant detail...
BRAF V600E MAP2K1 Q56_G61delinsR Binimetinib melanoma resistant detail...
BRAF V600E MAP2K1 Q56_G61delinsR Vemurafenib melanoma resistant detail...
BRAF V600E MAP2K1 Q56_G61delinsR Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 Q56_G61delinsR Encorafenib melanoma resistant detail...
BRAF V600E MAP2K1 Q56_G61delinsR Cobimetinib + Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 Q56_G61delinsR Dabrafenib + Trametinib melanoma resistant detail...
BRAF V600E MAP2K1 Q56_G61delinsR Binimetinib + Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 D303N Cobimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 G276W Trametinib melanoma sensitive detail...
BRAF V600E MAP2K1 G276W Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 D303N Binimetinib melanoma sensitive detail...
BRAF V600E MAP2K1 G276W Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 D303N Dabrafenib melanoma sensitive detail...
BRAF V600E MAP2K1 S241Y Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 G276W Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 D303N Encorafenib melanoma sensitive detail...
BRAF V600E MAP2K1 H100_I103delinsPL Dabrafenib melanoma resistant detail...
BRAF V600E MAP2K1 H100_I103delinsPL Encorafenib melanoma resistant detail...
BRAF V600E MAP2K1 D67N Cobimetinib melanoma resistant detail...
BRAF V600E MAP2K1 P124S Cobimetinib melanoma resistant detail...
BRAF V600E MAP2K1 G128D Cobimetinib melanoma resistant detail...
BRAF V600E MAP2K1 F53L Cobimetinib + Vemurafenib melanoma sensitive detail...
BRAF V600E MAP2K1 D67N Ulixertinib melanoma decreased response detail...
BRAF V600E MAP2K1 I99_K104del Ulixertinib melanoma decreased response detail...
BRAF V600E MAP2K1 P124S Ulixertinib melanoma decreased response detail...
BRAF V600E MAP2K1 D67N Ravoxertinib melanoma decreased response detail...
BRAF V600E MAP2K1 I99_K104del Ravoxertinib melanoma decreased response detail...
BRAF V600E MAP2K1 P124S Ravoxertinib melanoma decreased response detail...
BRAF V600E MAP2K1 E203K Ravoxertinib melanoma decreased response detail...
BRAF G464E PHI-501 melanoma predicted - sensitive detail...
NRAS Q61R PHI-501 melanoma predicted - sensitive detail...
BRAF V600E PHI-501 melanoma predicted - sensitive detail...
BRAF V600E BGB3245 melanoma predicted - sensitive detail...
NRAS G12S BGB3245 melanoma predicted - sensitive detail...
NRAS Q61K BGB3245 melanoma predicted - sensitive detail...
BRAF class 2 Exarafenib melanoma predicted - sensitive detail...
NRAS act mut Exarafenib melanoma predicted - sensitive detail...
NRAS Q61K Tunlametinib melanoma predicted - sensitive detail...
NRAS G12D Tunlametinib melanoma predicted - sensitive detail...
BRAF V600X ABM-1310 + Cobimetinib melanoma predicted - sensitive detail...
BRAF V600E IHMT-RAF-128 melanoma sensitive detail...
BRAF V600E Toripalimab-tpzi melanoma decreased response detail...
NRAS act mut Toripalimab-tpzi melanoma decreased response detail...
NRAS act mut Pembrolizumab melanoma decreased response detail...
KIT exon11 Pembrolizumab melanoma not predictive detail...
KIT exon13 Pembrolizumab melanoma not predictive detail...
KIT exon17 Pembrolizumab melanoma not predictive detail...
KIT exon17 Toripalimab-tpzi melanoma not predictive detail...
KIT exon13 Toripalimab-tpzi melanoma not predictive detail...
KIT exon11 Toripalimab-tpzi melanoma not predictive detail...
KIT exon9 Regorafenib melanoma predicted - sensitive detail...
KIT exon11 Regorafenib melanoma sensitive detail...
KIT exon13 Regorafenib melanoma sensitive detail...
KIT exon17 Regorafenib melanoma sensitive detail...
BRAF V600E SIJ777 melanoma sensitive detail...
BRAF G464E SIJ777 melanoma sensitive detail...
BRAF G469E SIJ777 melanoma sensitive detail...
BRAF D594G SIJ777 melanoma sensitive detail...
BRAF V600E NRAS Q61K Encorafenib + Talazoparib melanoma sensitive detail...
BRAF V600E Encorafenib + Talazoparib melanoma sensitive detail...
BRAF V600E NRAS Q61R Encorafenib + Talazoparib melanoma sensitive detail...
BRAF V600E NRAS Q61H Encorafenib + Talazoparib melanoma sensitive detail...
BRAF V600E Binimetinib + Encorafenib + Talazoparib melanoma sensitive detail...
BRAF V600E NRAS Q61R Binimetinib + Encorafenib + Talazoparib melanoma sensitive detail...
BRAF V600E NRAS Q61H Binimetinib + Encorafenib + Talazoparib melanoma sensitive detail...
BRAF V600E NRAS Q61K Encorafenib + Olaparib melanoma sensitive detail...
BRAF V600E NRAS Q61K Encorafenib + Rucaparib melanoma sensitive detail...
BRAF V600E NRAS Q61K Dabrafenib + Talazoparib melanoma sensitive detail...
BRAF V600E NRAS Q61R Dabrafenib melanoma resistant detail...
BRAF V600E NRAS Q61R Trametinib melanoma resistant detail...
BRAF V600E NRAS Q61R Dabrafenib + Trametinib melanoma predicted - sensitive detail...
BRAF V600E NRAS Q61K Dabrafenib + Talazoparib + Trametinib melanoma sensitive detail...
BRAF V600E NRAS Q61R Dabrafenib + Talazoparib + Trametinib melanoma sensitive detail...
BRAF V600E NRAS Q61K Talazoparib melanoma sensitive detail...
BRAF V600E NRAS Q61R Talazoparib melanoma sensitive detail...
BRAF V600E AZD3514 + Dabrafenib melanoma sensitive detail...
BRAF V600E ARCC4 + Dabrafenib melanoma sensitive detail...
BRAF V600E IMM-6-415 melanoma predicted - sensitive detail...
BRAF V600E Encorafenib + IMM-6-415 melanoma predicted - sensitive detail...
CDKN2A loss Abemaciclib + unspecified PD-1 antibody melanoma sensitive detail...
BRAF V600E Tovorafenib melanoma sensitive detail...
NRAS G12A Belvarafenib melanoma predicted - sensitive detail...
NRAS Q61L NST-628 melanoma predicted - sensitive detail...
NRAS Q61R NST-628 melanoma predicted - sensitive detail...
NRAS Q61X Tunlametinib melanoma predicted - sensitive detail...
NRAS G12X Tunlametinib melanoma predicted - sensitive detail...
NRAS G13X Tunlametinib melanoma predicted - sensitive detail...
BRAF V600E Tunlametinib + Vemurafenib melanoma sensitive detail...
BRAF V600E Tunlametinib melanoma sensitive detail...
BRAF V600E Ravoxertinib melanoma sensitive detail...
BRAF V600E Ravoxertinib + Vemurafenib melanoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00338377 Phase II Cyclophosphamide + Fludarabine Aldesleukin Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma Active, not recruiting USA 0
NCT00492505 Phase II Cisplatin + Sorafenib + Tamoxifen Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma Unknown status USA 0
NCT00538005 Phase Ib/II Bevacizumab + Oxaliplatin + Sorafenib Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma Unknown status USA 0
NCT00700882 Phase II Dasatinib Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery Completed USA 0
NCT00720785 Phase I Bortezomib Natural Killer Cells and Bortezomib to Treat Cancer Completed USA 0
NCT00925132 Phase Ib/II Decitabine + Panobinostat + Temozolomide Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat Terminated USA 0
NCT00976573 Phase II Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Everolimus + Paclitaxel Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma Completed USA 0
NCT01028222 Phase II Nilotinib A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation Completed USA | NLD | ITA | ESP | DEU | CAN | BEL | AUS 6
NCT01176474 Phase I NY-ESO-1 peptide vaccine Ipilimumab Nivolumab A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma Completed USA 0
NCT01218867 Phase Ib/II Anti-VEGFR2 CAR CD8 lymphocytes Cyclophosphamide Fludarabine Aldesleukin Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes Terminated USA 0
NCT01239134 Phase I TRX518 Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors Completed USA 0
NCT01258855 Phase II Aldesleukin Aflibercept Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Completed USA 0
NCT01274338 Phase III Ipilimumab Interferon alpha-2b Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Active, not recruiting USA | CAN 0
NCT01292655 Phase I BMS-906024 Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors Completed USA | CAN | AUS 0
NCT01303341 Phase I Riluzole + Sorafenib Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma Active, not recruiting USA 0
NCT01307267 Phase I Rituximab + Utomilumab Utomilumab A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab Completed USA | ITA | FRA | AUS 1
NCT01321437 Phase II Axitinib Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma Completed USA 0
NCT01323517 Phase II Dactinomycin + Ipilimumab + Melphalan Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity Completed USA 0
NCT01325441 Phase Ib/II Napabucasin + Paclitaxel A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Completed USA | CAN 0
NCT01351103 Phase I LGK974 LGK974 + Spartalizumab A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Active, not recruiting USA | NLD | ITA | FRA | ESP | DEU | CAN 0
NCT01358331 Phase I MK-8353 A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001) Terminated 0
NCT01366144 Phase I Paclitaxel Veliparib Carboplatin Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Active, not recruiting USA 0
NCT01391143 Phase I MGA271 Safety Study of MGA271 in Refractory Cancer Completed USA 0
NCT01409174 Phase Ib/II Cisplatin Ipilimumab Aldesleukin Temozolomide Interferon alpha-2b IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma Terminated USA 0
NCT01425008 Phase I Tovorafenib Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma Completed USA | GBR 0
NCT01436656 Phase I Encorafenib A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma Completed USA | FRA | ESP | AUS 3
NCT01449279 Phase I Ipilimumab Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy Completed USA 0
NCT01480154 Phase I Hydroxychloroquine + MK2206 Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer Active, not recruiting USA 0
NCT01495988 Phase II Bevacizumab Vemurafenib Trial of Vemurafenib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma Terminated USA 0
NCT01497808 Phase Ib/II Ipilimumab RADVAX: A Stratified Phase I/II Dose Escalation Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Metastatic Melanoma Completed USA 0
NCT01512251 Phase Ib/II Buparlisib + Vemurafenib BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma Completed USA 0
NCT01519323 Phase I Vemurafenib BRIM-P Terminated USA | ITA | GBR | FRA | ESP | DEU | AUS 3
NCT01533948 Phase II Axitinib Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery Terminated USA 0
NCT01543698 Phase Ib/II Binimetinib + Encorafenib Binimetinib + Encorafenib + Ribociclib A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors Completed USA | ITA | FRA | ESP | CAN | BEL | AUS 2
NCT01562899 Phase II Binimetinib + Ganitumab A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors Terminated USA | ITA | GBR | FRA | ESP | CAN | BEL | AUS 0
NCT01565837 Phase II Ipilimumab Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma Unknown status USA 0
NCT01585415 Phase I Vandetanib Vemurafenib and White Blood Cell Therapy for Advanced Melanoma Terminated USA 0
NCT01586195 Phase II Vemurafenib Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E Terminated USA 0
NCT01603212 Phase Ib/II Aldesleukin + Alpha 2 Interferon + Vemurafenib Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor Completed USA 0
NCT01619774 Phase II Dabrafenib + Trametinib An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor Completed USA 0
NCT01621490 Phase I Ipilimumab Nivolumab PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (PD-1) Completed USA | NLD | ESP 0
NCT01625351 Phase I Fludarabine Melphalan Busulfan Alemtuzumab A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas Completed USA 0
NCT01638676 Phase Ib/II Metformin + Vemurafenib A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients Recruiting USA 0
NCT01656642 Phase I Atezolizumab + Cobimetinib + Vemurafenib Atezolizumab + Vemurafenib A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma Completed USA 0
NCT01657591 Phase I Vemurafenib + XL888 Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma Completed USA 0
NCT01659151 Phase II Aldesleukin Fludarabine Vemurafenib Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 Metastatic Melanoma Active, not recruiting USA 0
NCT01667419 Phase III Vemurafenib BRIM8: A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma Completed USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 17
NCT01677741 Phase I Dabrafenib A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 2
NCT01682083 Phase III Dabrafenib + Trametinib Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). (COMBI-AD) Completed USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 13
NCT01682213 Phase II Dabrafenib Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation Completed USA 0
NCT01683188 Phase III Aldesleukin + Vemurafenib HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Terminated USA 0
NCT01689974 Phase II Ipilimumab Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma Terminated USA 0
NCT01696045 Phase II Ipilimumab Phase 2 Study of Ipilimumab in Children and Adolescents (12 to <18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma Terminated USA | GBR | FRA | ESP | DEU | BEL 2
NCT01701037 Phase II Dabrafenib + Trametinib Dabrafenib Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery Terminated USA 0
NCT01701674 Phase I Cyclophosphamide + Fludarabine Ipilimumab Aldesleukin Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts Active, not recruiting USA 0
NCT01703507 Phase I Ipilimumab Ipilimumab and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Melanoma With Brain Metastases Completed USA 0
NCT01708941 Phase II Interferon alpha-2b Ipilimumab Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT01721603 Phase II Dabrafenib A Phase 2 Prospective Trial of Dabrafenib With Stereotactic Radiosurgery in BRAFV600E Melanoma Brain Metastases Terminated USA 0
NCT01726738 Phase II Dabrafenib + Trametinib LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations Completed USA 0
NCT01738139 Phase I Imatinib + Ipilimumab Ipilimumab and Imatinib Mesylate in Advanced Cancer Completed USA 0
NCT01740297 Phase Ib/II Ipilimumab Talimogene laherparepvec Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma Completed USA | FRA | DEU 0
NCT01754376 Phase II Aldesleukin + Vemurafenib Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma Terminated USA 0
NCT01763164 Phase III Dacarbazine Binimetinib Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 16
NCT01765543 Phase I Rifampin + Vemurafenib A Pharmacokinetics Study to Investigate the Effect of Rifampin on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy Completed USA 4
NCT01767454 Phase I Dabrafenib + Ipilimumab + Trametinib Dabrafenib + Ipilimumab Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma Completed USA 0
NCT01777776 Phase Ib/II Encorafenib Encorafenib + Ribociclib Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. Terminated USA | NLD | CAN | AUS 0
NCT01781026 Phase II Vemurafenib Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases Completed USA 0
NCT01781572 Phase Ib/II Binimetinib + Ribociclib A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma Completed USA | NLD | ITA | DEU | AUS 0
NCT01810016 Phase I Ipilimumab NY-ESO-1 peptide vaccine NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma Terminated USA | AUS 0
NCT01813214 Phase II Vemurafenib The Effects of Vemurafenib on Immunity in Patients With Melanoma Terminated USA 0
NCT01820364 Phase II Binimetinib + Encorafenib Encorafenib + Ribociclib Buparlisib + Encorafenib Encorafenib + Infigratinib Capmatinib + Encorafenib LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma Terminated USA | ESP | DEU | CAN | AUS 1
NCT01826448 Phase I Pexidartinib + Vemurafenib A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma Terminated USA | FRA | DEU 0
NCT01827111 Phase II Ipilimumab + Nab-paclitaxel Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma Completed USA 0
NCT01835184 Phase I Cabozantinib + Vemurafenib Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery Terminated USA 0
NCT01841463 Phase Ib/II Vemurafenib + Voruciclib Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation Suspended USA 0
NCT01843738 Phase I Vemurafenib Radiation Use During Vemurafenib Treatment Withdrawn USA 0
NCT01844674 Phase I Tizanidine + Vemurafenib A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies Completed USA | CAN 3
NCT01876212 Phase II Dasatinib Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma Completed USA 0
NCT01876641 Phase Ib/II Decitabine + Vemurafenib Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Terminated USA 0
NCT01894672 Phase II Encorafenib BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation Completed USA 0
NCT01897116 Phase I Hydroxychloroquine + Vemurafenib A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma Completed USA 0
NCT01902173 Phase Ib/II Dabrafenib + Trametinib + Uprosertib Dabrafenib + Uprosertib Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer Active, not recruiting USA 0
NCT01904123 Phase I WP1066 A Phase I Trial of WP1066 Completed USA 0
NCT01909453 Phase III Vemurafenib Encorafenib Binimetinib + Encorafenib Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (COLUMBUS) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS 20
NCT01940809 Phase II Dabrafenib + Ipilimumab Ipilimumab + Nivolumab + Trametinib Dabrafenib + Ipilimumab + Trametinib Ipilimumab + Trametinib Dabrafenib + Ipilimumab + Nivolumab Ipilimumab Ipilimumab + Nivolumab Dabrafenib + Ipilimumab + Nivolumab + Trametinib Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery Terminated USA 0
NCT01941927 Phase II Trametinib + Uprosertib Trametinib With GSK2141795 in BRAF Wild-type Melanoma Completed USA 0
NCT01942993 Phase II Vemurafenib The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma Terminated USA 0
NCT01943422 Phase Ib/II Interferon alpha-2b + Vemurafenib Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma Completed USA 0
NCT01946789 Phase I Nogapendekin alfa inbakicept A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors Completed USA 0
NCT01950195 Phase I Ipilimumab SRS (Stereotactic Radiosurgery) Plus Ipilimumab Terminated USA 0
NCT01950390 Phase II Ipilimumab Bevacizumab + Ipilimumab Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot be Removed by Surgery Active, not recruiting USA 0
NCT01955460 Phase I Aldesleukin + Cyclophosphamide + Fludarabine + NGFR-transduced autologous T lymphocytes + TGFbDNRII-transduced autologous TILs Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma Active, not recruiting USA 0
NCT01961115 Phase II Epacadostat MELITAC 12.1 Peptide Vaccine INCB024360 and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma Completed USA 0
NCT01966445 Phase I GSK2849330 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors Completed USA | NLD | AUS 0
NCT01967823 Phase II Aldesleukin + Anti-NY ESO-1 mTCR PBL + Cyclophosphamide + Fludarabine T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer Completed USA 0
NCT01968109 Phase I Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS 5
NCT01970358 Phase I NeoVax melanoma vaccine A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma Completed USA 0
NCT01970527 Phase II Ipilimumab Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma Terminated USA 0
NCT01974258 Phase I Onartuzumab + Vemurafenib Cobimetinib + Onartuzumab Cobimetinib + Onartuzumab + Vemurafenib Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients Withdrawn USA 0
NCT01978236 Phase II Dabrafenib + Trametinib Dabrafenib Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites Terminated USA | AUS 0
NCT01988896 Phase I Atezolizumab + Cobimetinib A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors Completed USA | DEU | CAN | AUS 2
NCT01989585 Phase Ib/II Dabrafenib + Navitoclax + Trametinib Dabrafenib + Trametinib Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma Active, not recruiting USA 0
NCT01993719 Phase II Pembrolizumab Aldesleukin Fludarabine Cyclophosphamide Immunotherapy Using Tumor Infiltrating Lymphocytes Comparing 2 Different Conditioning Regimens for Patients With Metastatic Melanoma Completed USA 0
NCT02009397 Phase Ib/II Sargramostim Ipilimumab A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients Completed USA 0
NCT02009449 Phase I Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors Active, not recruiting USA 0
NCT02012231 Phase Ib/II PLX8394 Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. Terminated USA 0
NCT02013804 Phase I MEDI0680 A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies Completed USA 0
NCT02014909 Phase I CDX-3379 CDX-3379 + Vemurafenib CDX-3379 + Trastuzumab CDX-3379 + Cetuximab CDX-3379 + Erlotinib A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Completed USA 0
NCT02020707 Phase I Nab-paclitaxel Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery Active, not recruiting USA 0
NCT02027935 Phase II Aldesleukin Cyclophosphamide Ipilimumab Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 Completed USA 0
NCT02027961 Phase Ib/II Dabrafenib + Durvalumab + Trametinib Durvalumab + Trametinib Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone Completed USA | ITA | FRA | CAN 0
NCT02032810 Phase I Panobinostat Ipilimumab Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma Completed USA 0
NCT02036086 Phase II Cobimetinib + Vemurafenib Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases Active, not recruiting CAN 0
NCT02039947 Phase II Dabrafenib + Trametinib Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain Completed USA | ITA | FRA | ESP | DEU | CAN | AUS 0
NCT02043665 Phase I Coxsackievirus A21 Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) (STORM) Completed USA | GBR | AUS 0
NCT02047747 Phase II Dacomitinib A Phase II Study of Dacomitinib in Progressive Brain Metastases Terminated USA 0
NCT02050321 Phase II Acitretin + Vemurafenib A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma Terminated USA 0
NCT02054520 Phase II Ipilimumab Immunotherapy Study for Patients With Stage IV Melanoma Terminated USA 0
NCT02065466 Phase Ib/II Bevacizumab + Nab-paclitaxel + Temozolomide Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases Withdrawn USA 0
NCT02068079 Phase I Trientine + Vemurafenib A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma Withdrawn USA 0
NCT02073123 Phase Ib/II Ipilimumab Indoximod Study of IDO Inhibitor in Combination With Ipilimumab for Adult Patients With Metastatic Melanoma Completed USA 0
NCT02089685 Phase Ib/II Ipilimumab Peginterferon alfa-2b Pembrolizumab Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) Completed 0
NCT02094872 Phase II Doxorubicin Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic Completed USA 0
NCT02097225 Phase I Dabrafenib + Onalespib + Trametinib Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Unknown status USA 0
NCT02097732 Phase II Ipilimumab Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery Terminated USA 0
NCT02107755 Phase II Ipilimumab Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma Unknown status USA 0
NCT02110355 Phase Ib/II KRT-232 + Trametinib Dabrafenib + KRT-232 + Trametinib Dabrafenib + Trametinib A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma Completed USA | AUS 0
NCT02112032 Phase I Peginterferon alfa-2b + Pembrolizumab Treatment of Advanced Melanoma With MK-3475 and Peginterferon Completed USA 0
NCT02115243 Phase I Ipilimumab Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma Completed USA 0
NCT02117362 Phase I Ipilimumab Belapectin Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma Completed USA 0
NCT02120222 Phase I Selinexor Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery Completed USA 0
NCT02122861 Phase I ID-LV305 A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 Completed USA 0
NCT02126579 Phase Ib/II Poly ICLC Long peptide vaccine 7 Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists Completed USA 0
NCT02129075 Phase II NeoVax melanoma vaccine CDX-301 Rasdegafusp alfa CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma Completed USA 0
NCT02130466 Phase Ib/II Dabrafenib + Trametinib Pembrolizumab + Trametinib Dabrafenib + Pembrolizumab Dabrafenib + Pembrolizumab + Trametinib A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) Completed 0
NCT02138292 Phase I Digoxin + Trametinib A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma Completed USA 0
NCT02141542 Phase I Tremelimumab MEDI3617 Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma Completed USA 0
NCT02142218 Phase I Nivolumab Expanded Access Program With Nivolumab to Treat Melanoma No longer available USA | CAN 4
NCT02143050 Phase Ib/II Dabrafenib + Metformin + Trametinib Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients Withdrawn USA 0
NCT02145910 Phase I Vemurafenib Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases Withdrawn 0
NCT02156804 Phase II Nivolumab A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172) Completed NLD | ITA | GBR | ESP | DEU | BEL | AUT 13
NCT02158520 Phase II Ipilimumab Bevacizumab + Nab-paclitaxel Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery Completed USA 0
NCT02159066 Phase II Binimetinib + Encorafenib + Ribociclib Binimetinib + Encorafenib Binimetinib + Capmatinib + Encorafenib Binimetinib + Buparlisib + Encorafenib Binimetinib + Encorafenib + Infigratinib LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma Completed USA | NLD | ITA | GBR | ESP | DEU | CAN | AUS 1
NCT02173093 Phase Ib/II Aldesleukin + GD2Bi-aATC + Sargramostim Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma Unknown status USA 0
NCT02174172 Phase I Atezolizumab + Bevacizumab + Peg-interferon alfa-2a Atezolizumab + Interferon alpha-2b Atezolizumab + Peg-interferon alfa-2a Atezolizumab + Ipilimumab Atezolizumab + Obinutuzumab A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors Completed USA | NLD 0
NCT02178722 Phase Ib/II Epacadostat + Pembrolizumab Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers Completed USA 0
NCT02186249 Phase III Ipilimumab + Nivolumab Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Anti-CTLA-4 Treatment-Naïve Subjects With Unresectable or Metastatic Melanoma (CheckMate 218) No longer available USA | CAN 0
NCT02196181 Phase II Dabrafenib + Trametinib Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT02200562 Phase Ib/II Dabrafenib + Ipilimumab Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma Terminated USA 0
NCT02210104 Phase I Ipilimumab Cyclophosphamide Adoptive Therapy Using Antigen-Specific CD4 T-Cells Withdrawn 0
NCT02224781 Phase III Ipilimumab + Nivolumab Dabrafenib + Trametinib Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma Active, not recruiting USA 0
NCT02230306 Phase II Cobimetinib + Vemurafenib Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases Terminated USA 0
NCT02231775 Phase II Dabrafenib + Trametinib Combi-Neo Study for Stage IV Melanoma Active, not recruiting USA 0
NCT02257424 Phase Ib/II Dabrafenib + Hydroxychloroquine + Trametinib Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma (BAMM) Completed USA 0
NCT02259231 Phase Ib/II Ipilimumab Nivolumab Omaveloxolone RTA 408 Capsules in Patients With Melanoma - REVEAL Completed USA 0
NCT02263508 Phase Ib/II Pembrolizumab Talimogene laherparepvec MK-3475 With or Without Talimogene Laherparepvec in Unresected Melanoma Terminated USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 10
NCT02263898 Phase II Binimetinib + Encorafenib Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations Withdrawn USA 0
NCT02272855 Phase II Canerpaturev + Ipilimumab A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma Completed USA 0
NCT02296112 Phase II Trametinib Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations Completed USA 0
NCT02298959 Phase I Aflibercept + Pembrolizumab Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors Active, not recruiting USA | CAN 0
NCT02300935 Phase I Nab-paclitaxel + Trametinib Study of Trametinib and Nab-paclitaxel in Patients With Melanoma Withdrawn USA 0
NCT02302339 Phase II Glembatumumab vedotin A Study of Glembatumumab Vedotin in Patients With Advanced Melanoma Terminated USA 0
NCT02303990 Phase I Pembrolizumab RADVAX A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers Completed USA 0
NCT02306850 Phase II Pembrolizumab Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma Completed USA 0
NCT02307149 Phase I Coxsackievirus A21 Ipilimumab Study of Intratumoral CAVATAK (Coxsackievirus A21) and Ipilimumab in Patients With Advanced Melanoma Completed USA 0
NCT02308020 Phase II Abemaciclib A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain Completed USA | ITA | FRA | ESP | CAN | BEL | AUT | AUS 1
NCT02315066 Phase I PF-04518600 PF-04518600 + Utomilumab Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 Completed USA | NLD | FRA 1
NCT02318771 Phase I Pembrolizumab Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer Completed USA 0
NCT02320058 Phase II Ipilimumab + Nivolumab A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy (CheckMate 204) Completed USA 0
NCT02320305 Phase I MART-1 antigen GLA-SE + MART-1 antigen MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery Completed USA 0
NCT02327078 Phase Ib/II Epacadostat + Nivolumab A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers Completed USA | GBR 0
NCT02332668 Phase Ib/II Pembrolizumab A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) Recruiting USA | NLD | ITA | GBR | FRA | DEU 4
NCT02334735 Phase II Poly ICLC Autologous Dendritic Cells Pulsed with MART-1 NY-ESO-1 peptide vaccine A Comparison of Matured Dendritic Cells and Montanide&#174; in Study Subjects With High Risk of Melanoma Recurrence Completed USA 0
NCT02335918 Phase Ib/II Nivolumab + Varlilumab A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors Completed USA 0
NCT02339324 Phase I Interferon alpha-2b Pembrolizumab Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b Completed USA 0
NCT02339571 Phase II Sargramostim Nivolumab Ipilimumab Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Recruiting USA 0
NCT02346955 Phase I CM-24 CM-24 + Pembrolizumab Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) Terminated USA 1
NCT02360579 Phase II Lifileucel Study of LN-144, Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma (LN-144) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU 2
NCT02362594 Phase III Pembrolizumab Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054) Active, not recruiting 0
NCT02381314 Phase I Ipilimumab + MGA271 Safety Study of MGA271 in Combination With Ipilimumab in Refractory Cancer Completed USA 0
NCT02382549 Phase I 6MHP vaccine + Dabrafenib + Trametinib A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib (Mel61) Terminated USA 0
NCT02385669 Phase Ib/II 6MHP vaccine Ipilimumab A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma Terminated USA 0
NCT02387125 Phase I CMB305 A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 Terminated USA 0
NCT02388906 Phase III Nivolumab Ipilimumab Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | CAN | BEL | AUT | AUS 15
NCT02400385 Phase II Nivolumab + Sunitinib A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma Withdrawn USA 0
NCT02404441 Phase Ib/II Spartalizumab Phase I/II Study of PDR001 in Patients With Advanced Malignancies Completed USA | NLD | ITA | FRA | ESP | DEU | CAN 7
NCT02407171 Phase Ib/II Pembrolizumab Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC Completed USA 0
NCT02413827 Phase Ib/II Nivolumab + Varlilumab Rasdegafusp alfa Poly ICLC A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma Terminated USA 0
NCT02423863 Phase II Poly ICLC In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol Completed USA 0
NCT02425306 Phase Ib/II Cyclophosphamide 6MHP vaccine Poly ICLC Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma Terminated USA 0
NCT02427893 Phase III Cobimetinib Vemurafenib Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma Withdrawn USA 0
NCT02428712 Phase Ib/II PLX8394 A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors Active, not recruiting USA 0
NCT02432963 Phase I MVAp53 + Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Active, not recruiting USA 0
NCT02434354 Phase I Pembrolizumab A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma Completed USA 0
NCT02437136 Phase Ib/II Entinostat + Pembrolizumab Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma Completed USA 0
NCT02452281 Phase Ib/II Vitespen Ipilimumab Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma Withdrawn USA 0
NCT02452424 Phase Ib/II Pembrolizumab + Pexidartinib A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors Terminated USA 0
NCT02460224 Phase Ib/II Ieramilimab Spartalizumab Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Completed USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS 4
NCT02471846 Phase I Navoximod Atezolizumab A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors Completed USA | FRA | ESP 1
NCT02475213 Phase I MGA271 + Pembrolizumab Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer Completed USA 0
NCT02493361 Phase II Pembrolizumab IL-12 gene Trial of pIL-12/MK-3475 in Metastatic Melanoma Completed USA 0
NCT02498665 Phase I DSP-7888 A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies Completed USA 0
NCT02500576 Phase II Aldesleukin + Cyclophosphamide + Fludarabine + Mesna + Pembrolizumab MK-3475 With Lymphodepletion, TIL and High or Low Dose Interleukin-2 (IL-2) Completed USA 0
NCT02501096 Phase Ib/II Pembrolizumab Lenvatinib Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors Completed USA | ESP 1
NCT02506153 Phase III Interferon alpha-2b Pembrolizumab High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Active, not recruiting USA | CAN 1
NCT02509507 Phase I Pembrolizumab + Talimogene laherparepvec Talimogene laherparepvec Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab Completed USA | ESP | DEU | BEL | AUT | AUS 3
NCT02519322 Phase II Ipilimumab Nivolumab Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma Completed USA 0
NCT02521870 Phase I Pembrolizumab SD-101 A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma Terminated USA | NZL | DEU | AUS 0
NCT02526017 Phase I Cabiralizumab Nivolumab Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers Completed USA 0
NCT02528357 Phase I GSK3174998 Pembrolizumab GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors Completed USA | NLD | FRA | CAN 0
NCT02543645 Phase Ib/II Atezolizumab + Varlilumab A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer Terminated USA 0
NCT02553642 Phase II Nivolumab Ipilimumab Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) Completed USA 0
NCT02554812 Phase Ib/II Avelumab + PF-04518600 Avelumab + PD 0360324 Avelumab + Utomilumab Avelumab + PF-04518600 + Utomilumab A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) Terminated USA | GBR | FRA | CAN | AUS 3
NCT02557321 Phase Ib/II PV-10 Pembrolizumab PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma Active, not recruiting USA 0
NCT02559492 Phase I Epacadostat + Itacitinib Itacitinib + Parsaclisib INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors Terminated USA 0
NCT02561234 Phase I Pegzilarginase A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors Completed USA 0
NCT02565992 Phase I Coxsackievirus A21 + Pembrolizumab Phase I Study of Intratumoral CAVATAK and Pembrolizumab in Subjects With Advanced Melanoma Completed USA 0
NCT02574533 Phase I Pembrolizumab FANG vaccine Pilot Study of Vigil + Pembrolizumab for Advanced Melanoma Completed USA 0
NCT02575404 Phase I Belapectin Pembrolizumab GR-MD-02 Plus Pembrolizumab in Melanoma Patients Completed USA 0
NCT02576431 Phase II Larotrectinib A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) Active, not recruiting USA | FRA | ESP | DEU 14
NCT02576665 Phase I Toca 511 + Toca FC A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6) Terminated USA 0
NCT02587650 Phase II Ceritinib Capmatinib Regorafenib Entrectinib Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma Terminated USA 0
NCT02591654 Phase I Pembrolizumab MRI/PET Imaging to Assess Response to Pembrolizumab in Metastatic Melanoma Terminated USA 0
NCT02595866 Phase I Pembrolizumab Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms Active, not recruiting USA 0
NCT02599402 Phase III Ipilimumab + Nivolumab Nivolumab Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma Completed ITA | GBR | FRA | DEU | BEL | AUT | AUS 5
NCT02601950 Phase II Tazemetostat A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma Completed USA | ITA | GBR | FRA | DEU | CAN | BEL | AUS 1
NCT02608268 Phase Ib/II Spartalizumab Sabatolimab Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Terminated USA | NLD | ITA | CAN 5
NCT02617849 Phase II Carboplatin + Paclitaxel + Pembrolizumab Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma Active, not recruiting CAN 0
NCT02621021 Phase II Pembrolizumab Cyclophosphamide Fludarabine Aldesleukin A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab Suspended USA 0
NCT02628535 Phase I Obrindatamab Safety Study of MGD009 in B7-H3-expressing Tumors Terminated USA | CAN | AUS 0
NCT02637531 Phase I Pembrolizumab Eganelisib A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Unknown status USA 0
NCT02639026 Phase I Durvalumab + Tremelimumab Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers Completed USA 0
NCT02639546 Phase Ib/II Cobimetinib Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (iMATRIXcobi) Completed USA | ITA | GBR | FRA | ESP | DEU 1
NCT02643303 Phase Ib/II Durvalumab + Poly ICLC Tremelimumab A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Completed USA 0
NCT02644369 Phase II Pembrolizumab Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors (INSPIRE) Active, not recruiting CAN 0
NCT02644967 Phase Ib/II IMO-2125 + Ipilimumab IMO-2125 + Pembrolizumab A Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma Completed USA 0
NCT02645149 Phase II Trametinib Pazopanib Ceritinib Ribociclib + Trametinib Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (MatchMel) Recruiting AUS 0
NCT02646748 Phase I Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Completed USA 0
NCT02650635 Phase I Cyclophosphamide + Motolimod + Pegfilgrastim TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors Terminated USA 0
NCT02652455 Phase I Nivolumab Aldesleukin + Cyclophosphamide + Fludarabine Urelumab Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma Completed USA 0
NCT02656706 Phase II Ipilimumab + Nivolumab BrUOG 324: Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial Active, not recruiting USA 0
NCT02659540 Phase I Ipilimumab + Nivolumab A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma Completed USA 0
NCT02681549 Phase II Bevacizumab + Pembrolizumab Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer Recruiting USA 0
NCT02697591 Phase Ib/II INCAGN01876 An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors Completed USA 0
NCT02706353 Phase Ib/II Pembrolizumab + Sotigalimab APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma Active, not recruiting USA 0
NCT02711345 Phase I LTT462 A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers Terminated USA | ESP | DEU 3
NCT02714218 Phase III Ipilimumab + Nivolumab A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS 4
NCT02716948 Phase I Nivolumab Stereotactic Radiosurgery and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine Completed USA 0
NCT02718066 Phase Ib/II Chidamide + Nivolumab Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer Completed USA 0
NCT02719015 Phase Ib/II Pembrolizumab + rAd-hCD40L Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma Withdrawn 0
NCT02721459 Phase I Cobimetinib + Vemurafenib + XL888 XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma Active, not recruiting USA 0
NCT02723006 Phase I Nivolumab + Tovorafenib MLN1202 + Nivolumab Ipilimumab + Nivolumab + Vedolizumab Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma Terminated USA 0
NCT02723955 Phase I GSK3359609 GSK3359609 + Pembrolizumab Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1) Completed USA | NLD | ITA | FRA | ESP | CAN | AUS 2
NCT02736123 Phase Ib/II Nivolumab Ipilimumab + Nivolumab Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone Withdrawn USA 0
NCT02740920 Phase II Pembrolizumab Assessment of Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography (CT) Texture Analysis as a Predictive Biomarker Terminated CAN 0
NCT02743819 Phase II Ipilimumab + Pembrolizumab Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody Active, not recruiting USA 0
NCT02748564 Phase II Aldesleukin + Pembrolizumab Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma Terminated USA 0
NCT02752074 Phase III Epacadostat + Pembrolizumab Pembrolizumab A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma Completed USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 12
NCT02760797 Phase I Emactuzumab + Selicrelumab A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors Completed USA | FRA | BEL 0
NCT02796352 Phase II Aldesleukin A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study Terminated USA 0
NCT02799095 Phase I ALKS 4230 A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors Completed USA | ESP | CAN | BEL | AUS 2
NCT02807844 Phase Ib/II MCS110 + Spartalizumab Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies Completed USA | ITA | FRA | ESP | DEU | BEL 5
NCT02812693 Phase Ib/II Imatinib + Pembrolizumab Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification Withdrawn 0
NCT02816021 Phase II Azacitidine + Pembrolizumab Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma Active, not recruiting USA 0
NCT02818023 Phase I Cobimetinib + Pembrolizumab + Vemurafenib Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma Terminated USA 0
NCT02819843 Phase II Talimogene laherparepvec A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors Completed USA 0
NCT02823405 Phase I Pembrolizumab + X4P-001 Neoadjuvant X4P-001 and Pembrolizumab in Patients With Resectable Melanoma (X4P-001-MELA) Completed USA 0
NCT02839694 Phase I Decitabine + Tetrahydrouridine Celecoxib + Decitabine + Tetrahydrouridine Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy Withdrawn 0
NCT02857270 Phase I LY3214996 Gemcitabine + LY3214996 + Nab-paclitaxel LY3214996 + Midazolam Abemaciclib + LY3214996 A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Completed USA | FRA | AUS 1
NCT02857569 Phase Ib/II Ipilimumab + Nivolumab A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma (NIVIPIT) Completed FRA 0
NCT02858869 Phase 0 Pembrolizumab Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases Completed USA 0
NCT02870244 Phase I Autologous TIL 13831 TCR transduced T cells Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes Recruiting USA 0
NCT02880371 Phase Ib/II ARRY-382 + Pembrolizumab A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors Terminated USA 0
NCT02889861 Phase Ib/II Tebentafusp IMCgp100-401 Rollover Study Terminated USA | GBR 0
NCT02897765 Phase I Nivolumab NEO-PV-01 + Poly ICLC A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer Completed USA 0
NCT02908672 Phase III Cobimetinib + Vemurafenib Atezolizumab + Cobimetinib + Vemurafenib A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma Active, not recruiting USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 8
NCT02910700 Phase II Nivolumab + Trametinib Dabrafenib + Nivolumab + Trametinib Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib in Patients With BRAF or NRAS-mutated Metastatic Melanoma Active, not recruiting USA 0
NCT02915666 Phase I Dabrafenib + Digoxin + Trametinib A Clinical Trial of Patients With Melanoma Withdrawn USA 0
NCT02923349 Phase Ib/II INCAGN01949 A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors Completed USA | GBR | ESP 1
NCT02935790 Phase I